

Complex II ambiguities—FADH₂ in the electron transfer system

Received for publication, July 3, 2023, and in revised form, November 1, 2023. Published, Papers in Press, November 22, 2023.
<https://doi.org/10.1016/j.jbc.2023.105470>

Erich Gnaiger*

From the Oroboros Instruments, Innsbruck, Austria

Reviewed by members of the JBC Editorial Board. Edited by Joan B. Broderick

The prevailing notion that reduced cofactors NADH and FADH₂ transfer electrons from the tricarboxylic acid cycle to the mitochondrial electron transfer system creates ambiguities regarding respiratory Complex II (CII). CII is the only membrane-bound enzyme in the tricarboxylic acid cycle and is part of the electron transfer system of the mitochondrial inner membrane feeding electrons into the coenzyme Q-junction. The succinate dehydrogenase subunit SDHA of CII oxidizes succinate and reduces the covalently bound prosthetic group FAD to FADH₂ in the canonical forward tricarboxylic acid cycle. However, several graphical representations of the electron transfer system depict FADH₂ in the mitochondrial matrix as a substrate to be oxidized by CII. This leads to the false conclusion that FADH₂ from the β -oxidation cycle in fatty acid oxidation feeds electrons into CII. In reality, dehydrogenases of fatty acid oxidation channel electrons to the Q-junction but not through CII. The ambiguities surrounding Complex II in the literature and educational resources call for quality control, to secure scientific standards in current communications of bioenergetics, and ultimately support adequate clinical applications. This review aims to raise awareness of the inherent ambiguity crisis, complementing efforts to address the well-acknowledged issues of credibility and reproducibility.

Current studies on cellular and mitochondrial bioenergetics sparked a new interest in the tricarboxylic acid (TCA) cycle also known as the citric acid cycle or Krebs cycle (1–4). TCA cycle metabolites are oxidized while reducing NAD⁺ to NADH+H⁺ in the forward cycle or are transported into the cytosol mainly by passive diffusion dependent on concentration differences across the mitochondrial membranes (5, 6). Respiratory Complex II (CII, succinate dehydrogenase SDH; succinate-ubiquinone oxidoreductase SQR; EC 1.3.5.1)—discovered in 1909 (7, 8)—has a unique position in both the TCA cycle and the mitochondrial membrane-bound electron transfer system (membrane-ETS). All genes for CII are nuclear-encoded, with exceptions in some red algae and land plants (9, 10). SQRs favor the oxidation of succinate and reduction of quinone in the canonical forward direction of the TCA cycle (11). Operating in the reverse direction, quinol:fumarate reductases (QFRs, fumarate reductases) reduce

fumarate and oxidize quinol (12, 13). The reverse TCA cycle has gained interest in studies ranging from metabolism in anaerobic animals (14, 15), thermodynamic efficiency of anaerobic and aerobic ATP production (16), reverse electron transfer and production of reactive oxygen species (17–19), hypoxia and ischemia-reperfusion injury (20), to evolution of metabolic pathways (21, 22). In cancer tissues, CII plays a key role in metabolic remodeling (23, 24). Beyond its role in electron transfer in the TCA cycle and the membrane-ETS, CII and succinate serve multiple functions in metabolic signaling (25–27). CII is thus a target of current pharmacological developments (28, 29).

The pyridine derivative NAD⁺ is reduced to NADH+H⁺ during the oxidation of pyruvate and through redox reactions catalyzed by TCA cycle dehydrogenases (DH) including isocitrate DH, oxoglutarate (α -ketoglutarate) DH, and malate DH. In turn, NADH+H⁺ are the substrates in the oxidation reaction catalyzed by Complex I (CI; NADH:ubiquinone oxidoreductase; EC 1.6.5.3) which is linked to the reduction of the prosthetic group flavin mononucleotide FMN to FMNH₂ and regeneration of NAD⁺. Likewise, the prosthetic group flavin adenine dinucleotide FAD is reduced to FADH₂ during the oxidation of succinate by CII (succinate DH). Confusion emerges, however, when NADH and FADH₂ are considered as the reduced substrates feeding electrons from the TCA cycle into the “respiratory chain”—rather than NADH and succinate. This “Complex II ambiguity” has deeply penetrated the scientific literature on bioenergetics without sufficient quality control. Therefore, a critical literature survey is needed to ensure scientific standards in communications on bioenergetics. By drawing attention to widespread CII ambiguities, subsequent erroneous portrayal and misinformation are revealed on the position of CII in pathways of energy metabolism, particularly in graphical representations of the mitochondrial electron transfer system.

While ambiguity is linked to relevant issues of reproducibility, it extends to the communications space of terminological and graphical representations of concepts (30). Type 1 ambiguities are the inevitable consequence of conceptual evolution, in the process of which ambiguities are replaced by experimentally and theoretically supported paradigm shifts to clear-cut theorems. In contrast, type 2 ambiguities are traced in publications that reflect merely a disregard and ignorance of established concepts without any attempt to justify the inherent

* For correspondence: Erich Gnaiger, erich.gnaiger@oroboros.at.

deviations from high-quality science. There are many shades of grey between these types of ambiguity. The Cambridge Dictionary defines ambiguity as “*the fact of something having more than one possible meaning and therefore possibly causing confusion*” <https://dictionary.cambridge.org/dictionary/english/ambiguity> (retrieved 2023–09–23). This is opposite to “productive ambiguity” (30) used in the sense of various isomorphic or complementary representations, describing a concept from different points of view. The word relates etymologically to “double meaning” and “equivocalness,” from *ambi* (around, on both sides).

Ambiguities regarding Complex II (CII) emerge on several fronts. First, they arise when portraying FADH₂ within the mitochondrial matrix as both a product of succinate dehydrogenase (SDH) and a substrate of CII. Although misconstrued, this may be seen as an electron transfer from FADH₂ in the SDHA subunit of CII to ubiquinone. Second, numerous publications introduce ambiguity through the presentation of incorrect figures, depicting FADH₂ instead of succinate as the substrate for CII. Third, this confusion extends to the representation of the reduced flavin adenine dinucleotide (FADH₂) in various misconstrued forms, such as FADH or FADH⁺, or the oxidized form FAD as FAD⁺. Fourth, when illustrating the oxidation of FADH₂, several figures show reactions like FADH₂ → FAD + H⁺ or FADH₂ → FAD + 2H⁺. These hydrogen ions H⁺ introduce a spectrum of uncertainties and blur the line between ambiguous interpretations and indisputable misinformation. Aiming at an open frame for discussion, the term ambiguity is used here in a collegial manner rather than a punctilious one. Nevertheless, these ambiguities have been a source of confusion even among established authors of specialized research reports, highly cited reviews, and editorials in leading journals. CII ambiguities have led to erroneous conclusions as will be discussed below.

Electron flow through CI and CII to the coenzyme Q junction

The reduced flavin groups FMNH₂ of flavin mononucleotide and FADH₂ of flavin adenine dinucleotide are at functionally comparable levels in the electron transfer through CI and CII, respectively (Fig. 1, A and B). FMNH₂ and FADH₂ are reoxidized downstream in CI and CII, respectively, by electron transfer or more explicitly by transfer of 2{H⁺ + e⁻} to the ETS-reactive coenzyme Q (Q) (31), reducing ubiquinone (UQ) to ubiquinol (UQH₂). The convergent architecture of the electron transfer system (ETS; in contrast to a linear electron transfer chain ETC; a chain's length used to be a linear measure) with multiple branches feeding into the Q-junction is emphasized in Figure 1, C and D (6, 32). Comparable to CII, several respiratory Complexes are localized in the mitochondrial inner membrane (mtIM) which catalyze electron transfer converging at the Q-junction, including electron transferring flavoprotein DH Complex in fatty acid oxidation, glycerophosphate DH Complex, sulfide-ubiquinone oxidoreductase, choline DH, dihydro-*o*-rotate DH, and proline DH (3, 6, 32–34). Electron transfer and corresponding capacities of

oxidative phosphorylation (OXPHOS) are classically studied in mitochondrial preparations as oxygen consumption supported by various fuel substrates undergoing partial oxidation in the mt-matrix, such as pyruvate, malate, succinate, and others (6). Therefore, the matrix component of the ETS (matrix-ETS) is distinguished from the ETS bound to the mtIM (membrane-ETS; Fig. 1C) (2).

In most flavin-linked dehydrogenases the flavin adenine nucleotide is a tightly bound prosthetic group. In CII, it is even covalently and thus permanently bound to the enzyme during the catalytic cycle when the redox state is regenerated in each enzymatic turnover, as documented in early reports (35) and summarized in classical textbooks (36, 37). Structural studies of CII have expanded our knowledge of the mechanism of enzyme assembly (13), enzyme structure (38–40), kinetic regulation of CII activity (41, 42), and associated pathologies (3, 26–29).

H⁺-linked two-electron transfer from succinate to flavin adenine dinucleotide reduces the oxidized prosthetic group FAD to FADH₂ with formation of fumarate. This H⁺-linked electron transfer through CII is not coupled to H⁺ translocation across the mtIM. Hence, CII is not a H⁺ pump in contrast to the respiratory Complexes CI, CIII, and CIV through which electron transfer—more appropriately 2{H⁺ + e⁻} transfer (Table 1)—drives and maintains the protonmotive force.

The reversible oxidoreduction of dicarboxylate (succinate/fumarate) is catalyzed in the soluble domain of CII extending from the mtIM into the mt-matrix. Succinate donates 2{H⁺ + e⁻} to FAD bound to the subunit SDHA which contains the catalytically active dicarboxylate binding site. The oxidized yellow (450 nm) form FAD functions as the hydrogen acceptor from succinate to the reduced internal product FADH₂ while fumarate is formed as the oxidized external product in the TCA cycle. FADH₂ relays electrons further through a series of iron-sulfur redox centers in SDHB to reduce UQ to UQH₂ in the membrane domain harboring SDHC and SDHD (9–13, 39) (Fig. 1E).

Simple arrows (Fig. 1, A–C) or pairs of rounded arrows—an external arrow touching the enzyme and an internal arrow within the enzyme—indicate chemical reactions of H⁺-linked electron transfer (Fig. 1, D and E). The term H⁺-coupled electron transfer (43) is replaced by H⁺-linked electron transfer, to avoid confusion with *coupled* H⁺ translocation. Caution is warranted to distinguish three types of transformation with hydrogen ions, for which IUPAC suggests the term ‘hydrons’ (44): (i) Acid-base reactions equilibrate fast without catalyst. (ii) ‘The terms reducing equivalents or electron equivalents are used to refer to electrons and/or hydrogen atoms participating in oxidoreductions’ (36). Redox transfer of hydrogen atoms is slow and depends on a catalyst. The symbol 2{H⁺ + e⁻} is introduced to indicate H⁺-linked electron transfer of two hydrons and two electrons in a redox reaction. (iii) Vectorial H⁺ transport is either active with translocation through H⁺ pumps or passive as diffusion driven by the electrochemical pressure difference across cellular compartments (6) (Table 1).




Figure 1. Complex II (SDH) integrates H⁺-linked electron transfer in the TCA cycle (matrix-ETS) and the electron transfer system (membrane-ETS) of the mt-inner membrane (mtIM). A, NADH+H⁺ and (B) Succinate are substrates of 2{H⁺ + e⁻} transfer to the prosthetic groups FMN and FAD as the corresponding electron acceptors in CI and CII, respectively. C, symbolic representation of ETS pathway architecture. Electron flow converges at the N-junction, NAD⁺+2{H⁺ + e⁻} → NADH+H⁺, and from NADH+H⁺ and succinate S at the Q-junction, UQ+2{H⁺ + e⁻} → UQH₂. CIII passes electrons to cytochrome c and in CIV to molecular O₂, 2{H⁺ + e⁻}+0.5 O₂ → H₂O. D, NADH and NAD⁺ cycle between different matrix-dehydrogenases and CI, whereas FAD and FADH₂ remain permanently bound within the same CII-enzyme molecule during the catalytic cycle. Succinate and fumarate indicate the chemical entities irrespective of ionization, whereas charges are shown in NADH (uncharged), NAD⁺, and H⁺. Joint pairs of half-circular arrows distinguish the chemical reaction of electron transfer 2{H⁺ + e⁻} to CI and CII from vectorial H⁺ translocation across the mtIM (H⁺_{neg} → H⁺_{pos}). CI, CIII, and CIV pump hydrogen ions from the negatively (neg; yellow) to the positively charged compartment (pos; grey, intermembrane space). E, Iconic representation of SDH subunits. SDHA catalyzes the oxidation succinate → fumarate + 2{H⁺ + e⁻} and reduction FAD+2{H⁺ + e⁻} → FADH₂ in the soluble domain of CII. The iron-sulfur protein SDHB transfers electrons through Fe-S clusters to the mtIM domain where ubiquinone UQ is reduced to ubiquinol UQH₂ in SDHC and SDHD.

Table 1
Three distinct types of transformation with hydrogen ions (hydrons) H⁺

Transformation	Equation	Type
1. Acid-base equilibrium	H ₃ O ⁺ ↔ H ₂ O + H ⁺ (a) H ₂ CO ₃ ↔ HCO ₃ ⁻ + H ⁺ (b)	Scalar, chemical, fast
2a. H ⁺ -linked electron transfer, oxidation	Malate ²⁻ → Oxaloacetate ²⁻ + 2{H ⁺ +e ⁻ } (c) Succinate ²⁻ → Fumarate ²⁻ + 2{H ⁺ +e ⁻ } (d)	Scalar, chemical, slow
2b. H ⁺ -linked electron transfer, reduction	2{H ⁺ +e ⁻ } + NAD ⁺ → NADH+H ⁺ (e) 2{H ⁺ +e ⁻ } + E-FAD → E-FADH ₂ (f)	Scalar, chemical, slow
3. Transport, translocation	pumping: H ⁺ _{neg} → H ⁺ _{pos} (g) diffusion: H ⁺ _{pos} → H ⁺ _{neg} (h)	Vectorial, Compartmental, transmembrane

Sources and consequences of Complex II ambiguities

'No representation is ever perfectly expressive, for if it were it would not be a representation but the thing itself' (30).

Ambiguities emerge if the representation of a concept is vague to an extent that allows for equivocal interpretations. As a consequence, even a basically clear concept (Fig. 1) may be communicated as a divergence from an established 'truth'. The comparison between NADH linked to CI and FADH₂ (instead of succinate) linked to CII leads us astray, as illustrated by the following textbook quotes (45) which require correction (Fig. 2).

- (1) *'Electrons from NADH enter the electron transport chain in complex I, .. A distinct protein complex (complex II), which consists of four polypeptides, receives electrons from the citric acid cycle intermediate, succinate' (Fig. 2B; ref. (45)). 'These electrons are transferred to FADH₂, rather than to NADH, and then to coenzyme Q.'* Note the suggestive comparison of FADH₂ and NADH.
- (2) *'In contrast to the transfer of electrons from NADH to coenzyme Q at complex I, the transfer of electrons from FADH₂ to coenzyme Q is not associated with a significant decrease in free energy and, therefore, is not coupled to ATP synthesis.'* Note that CI catalyzes electron transfer from NADH to coenzyme Q. In contrast, electron transfer from FADH₂ to coenzyme Q is downstream of succinate oxidation by CII. Thus instead of the Gibbs force ('decrease in free energy') in FADH₂→Q, the total Gibbs force (6) in S→Q must be accounted for. In contrast to the extensive quantity Gibbs energy [J], Gibbs force [J·mol⁻¹] is an

intensive quantity expressed as the partial derivative of Gibbs energy [J] per advancement of a reaction [mol] (6, 46). (In parentheses: Redox-driven proton translocation must be distinguished from phosphorylation of ADP driven by the protonmotive force).

- (3) *'.. electrons from succinate enter the electron transport chain via FADH₂ in complex II.'* Note that CII receives electrons from succinate *via* FAD. The ambiguity is caused by a lack of unequivocal definition of the electron transfer system ('electron transport chain'). Two contrasting definitions are implied of the "electron transport chain" or ETS. (a) CII is part of the ETS. Hence electrons enter the ETS in the succinate branch from succinate but not from FADH₂ – from the matrix-ETS to the membrane-ETS (Fig. 1, C and D). (b) If electrons enter the 'electron transport chain via FADH₂ in complex II', then subunit SDHA would be upstream and hence not part of the ETS (to which conclusion obviously nobody would agree). Electrons enter CII and thus the membrane-ETS from succinate (Fig. 1) but not from FADH₂ as the "product" of succinate dehydrogenase in the TCA cycle, as erroneously shown in Figure 3, A and B.

The FADH₂ - FAD confusion in the succinate-pathway

'Like drops of water on stone, one drop will do no harm, but over time, grooves are cut deep' (47).

The narrative that the reduced cofactors NADH and FADH₂ feed electrons from the TCA cycle into the mitochondrial electron transfer system causes confusion. As a consequence,




Figure 2. Electron transfer to CI and CII. Zoom into figures of ref. (45). A, H⁺ (marked) is shown to be produced in H⁺-linked electron transfer instead of being consumed (cf. Fig. 1A). B, Marked quote inserted from the legend to Fig. 10.9 of ref. (45).

the prosthetic group FADH₂ appears erroneously as the substrate of CII in the ETS linked to succinate oxidation. This error is widely propagated in publications found from 2001 to 2023 (4, 23, 48–355) and numerous educational websites (356). The following examples illustrate the transition from ambiguity to erroneous representation.

- (1) Ambiguities appear in graphical representations, where FADH₂ is the product of SDH and the substrate of CII – synonymous with SDH (explicit in Figure 3, A and B; implicit in Fig. 3C).
- (2) Ambiguity evolved to misconception in graphical representations (Fig. 3, D–F).
- (3) Instead of NADH+H⁺→NAD⁺ (Fig. 1A) there appears NADH→NAD⁺ +H⁺ or +2H⁺ and by analogy FADH₂→FAD+2H⁺ (Fig. 3, G and H). The analogy

- NADH→NAD⁺ is taken further to include a charge for FAD or even writing FADH⁺ (Fig. 3, I and J). Disturbing patterns are shown in various figures with analogous representations of oxidation of NADH and FADH₂ (Table 2).
- (4) Finally, error propagation from graphical representation (Fig. 3) leads to misinformation in the text: ‘SDH reduces FAD to FADH₂, which donates its electrons to complex II’; ‘each complete turn of the TCA cycle generates three NADH and one FADH₂ molecules, which donate their electrons to complex I and complex II, respectively’; ‘complex I and complex II oxidize NADH and FADH₂, respectively’ (4).

Clarification is required (see page 48 in ref. (6)) to counteract the accelerating propagation of a fundamental bio-energetic misunderstanding (Fig. 3K). Electron transfer from succinate in the TCA cycle to the prosthetic group FAD is a

Table 2
Misconceptions in graphical representations of electron entry into CI and CII

CI e-input errors		Ref.	CII e-input errors		Ref.
NADH	→ NAD ⁺ + H ⁺	(45, 97, 99)	FADH ₂	→ FAD	(4, 23, 48–99) ^a
NADH	→ NAD	(52, 56) ^b	FADH ₂	→ FAD	(52, 56) ^b
NAD	→ NADH	(56) ^c	FAD	→ FADH ₂	(56) ^c
NADH	→ NAD ⁺ + H ⁺	(106, 122, 156, 157, 163, 172, 181)	FADH ₂	→ FAD	(100–187) ^d
NADH	→ NAD	(123, 125, 130, 168, 177, 184)			
NADH + H ⁺	→ NAD ⁺ + 2H ⁺	(149)			
NADH	→ NAD ⁺ + H ⁺	(227, 238)	FADH ₂	→	(188–240) ^e
NADH	→ NAD	(220, 227)			
NADP		(240)			
NADH	→ NAD ⁺ + H ⁺	(241)	FADH ₂	→ FAD + H ⁺	(241)
NADH	→ NAD ⁺ + H ⁺	(242, 248, 259–261, 265, 268, 274)	FADH ₂	→ FAD + 2H ⁺	(242–280) ^f
NADH	→ NAD + H ⁺	(243, 245, 271, 278)			
NADH	→ NAD ⁺ + 2H ⁺	(244, 246, 247, 249–258, 262–264, 266, 267, 269, 270, 273, 275–280)			
NADH	→ NAD + 2H ⁺	(272)	FADH ₂	→ FAD ⁺	(281–310) ^g
NADH	→ NAD	(286)	FADH ₂	→ FAD ⁺	(307)
NADH + H	→ NAD ⁺	(307)	FADH ₂	→ FAD ⁺ + H ⁺	(311)
NADH	→ NAD + H ⁺	(311)	FADH ₂	→ FAD ⁺ + H ⁺	(312)
NADH	→ NAD ⁺ + H ⁺	(312)	FADH ₂	→ FAD ⁺ + 2H ⁺	(313–319)
NADH	→ NAD ⁺ + H ⁺	(313, 315, 316, 318)	FADH ₂	→ FAD ⁺ + 2H ⁺	
NADH	→ NAD ⁺ + 2H ⁺	(314, 317, 319)	FADH ₂	→ FAD ²⁺	(320)
NADH + H ⁺	→ NADH	(321)	FADH ₂	→ FADH	(321–329)
NADH	→ NAD	(326)			
NADH	→ NAD ⁺ + H ⁺	(330)	FADH ₂	→ FADH + H ⁺	(330)
			FADH ₂	→ FADH ⁺	(331, 332) ^h
			FADH	→	(333, 334)
NADH	→ NAD + H ⁺	(335, 336)	FADH	→ FAD	(335, 336)
			FADH	→ FAD ⁺	(337–339)
NADH	→ NAD ⁺ + H ⁺	(340)	FADH	→ FAD ⁺ + H ⁺	(340)
NADH	→ NAD ⁺ + H ⁺	(341)	FADH	→ FAD ⁺ + 2H ⁺	(341)
			FADH ⁺	→ FAD	(342)
			FAD	→ FADH ₂	(343–345) ⁱ
			FAD ⁺	→ FADH ₂	(346)
			FADH ₂	→ FAD + 2H ⁺	(347) ^j
			FADH ₂	→ CI → CII	(348)
			ETF	→ CII → CIII	(349–355) ^k
NADH	→ NAD ⁺ + H ⁺	(241)	CI	→ CII → CIII	(129, 166, 171, 176, 183, 223, 241, 339, 348, 373)
NAD ⁺ + H ⁺	→ NADH	(386) ^l			

2[H⁺ + e⁻] is donated to CI in the oxidation NADH + H⁺ → NAD⁺ + 2[H⁺ + e⁻], and to CII in the oxidation Succinate²⁻ → Fumarate²⁻ + 2[H⁺ + e⁻].

^a FAD a substrate of SDH and FADH₂ a substrate of CI (Fig. 3, A–C).

^b Oxidation by CI and CII of NADH and FADH₂, respectively, from the TCA cycle.

^c Reduction by CI and CII of NAD (NAD⁺) and FAD from β-oxidation.

^d Figure 3, D and E.

^e Figure 3F.

^f Figure 3, G and H.

^g Figure 3I.

^h Figure 3J.

ⁱ Electron transfer into the Q-junction does not occur from a common FADH₂ pool from CII and CGpDH, as Fig. 6 of ref. (345) suggests, but through functionally separate branches converging at the Q-junction.

^j Paradoxically, oxidation of FADH₂ is linked to oxidation of succinate with formation of FAD and fumarate and 2H⁺; Succinate + FADH₂ → FAD + Fumarate + 2H⁺.

^k The pathway is either shown from β-oxidation to CII or explicitly from ETF to CII (Fig. 5).

^l Fig. 7 of ref. (386) shows reduction of NAD⁺ by CI, where it should be oxidation of NADH.





Figure 3. Complex II ambiguities. FADH₂ is depicted as (1) product and (2) substrate of Complex II by (A) (4), (B) (80), as in ref. (48–99, 104, 192–194, 199, 201–206, 209–211, 213, 215–220, 222, 225–227, 231, 233, 236, 239–241, 245, 271–280, 285, 291–295, 304–306, 308, 311, 312, 314, 320, 330). NADH and NAD⁺ cycle between different types of enzymes (yellow circle), in contrast to the FAD/FADH₂ cycle located within the same enzyme molecule (SDH and CII are synonyms). C, from ambiguous NADH-FADH₂ analogy (73) to (D) graphical misconception (58), as in ref. (100–240). NADH and FADH₂ at the doors of CI and CII, respectively, shown by (E) an international team (169) and (F) an international consortium suggesting guidelines (198); FADH₂ cannot enter – it functions always inside CII like FAD which receives electrons from the substrate succinate. G, the redox reaction of the flavin adenine dinucleotide is copied from the nicotinamide adenine dinucleotide with an unjustified indication of 2H⁺ formation in the mt-matrix, confusing in the context of the protonmotive force. The figure from ref. (264) is similar or identical to zooms into 33 figures from ref. (49, 57, 70, 72, 133, 154, 186, 244, 246, 249, 251–255, 257, 262–264, 267, 269, 270, 272, 273, 275–280, 317, 319). H, the CII ambiguity in FADH₂→FAD+2H⁺ (242–280) fires back at the CI-catalyzed reaction when NAD⁺ is shown like FAD as NAD without charge (245, 271). I, the NADH→NAD⁺ analogy is taken to the level of copying a charge to FAD⁺ ((288), as in (281–319)) or (J) FADH⁺ ((331), as in (332)). K,

redox reaction, where oxidation (ox) of succinate yields 2{H⁺ + e⁻}—two hydrons and two electrons—which are donated in the reduction (red) of FAD to FADH₂ (Table 1),



The net redox reaction equation is



Commonly the charges of succinate, fumarate (Equation 1), and other metabolites are not shown explicitly to simplify graphical representations of metabolic pathways. But NAD⁺ (oxidized) must be distinguished from NAD (total NAD⁺ + NADH). In 2{H⁺ + e⁻} + NAD⁺ → NADH+H⁺ the final H⁺ is frequently omitted (Fig. 3). One hydrogen atom is transferred directly from the hydrogen donor (e.g. malate) to NAD⁺ without dilution by the aqueous H⁺ whereas the other forms an aqueous hydrogen ion (32). The equilibrium (Equation e in Table 1) depends on pH. In contrast, Equation 1b (Equation f in Table 1) is independent of pH. The fundamental difference between 2H⁺ and 2{H⁺ + e⁻} in Equation e (Table 1) is lost in representations such as Figure 3, G and H.

In summary, the two-electron oxidation of succinate is redox-linked to the reduction of SDHA-FAD to SDHA-FADH₂, and the final electron transfer step in CII reduces UQ to UQH₂. In terms of electron entry into CII, many publications show it in the wrong direction, that is, oxidation of FADH₂ as an electron donor from the TCA cycle to CII (Fig. 3). This erroneous presentation has the logical consequence of putting CII into the wrong position of mitochondrial core energy metabolism. Several electron transfer pathways reduce the prosthetic group FAD of different enzymes to FADH₂ and then converge separately at the Q-junction (Fig. 4). In ambiguous graphs, CII can be seen as an enzyme receiving reducing equivalents from FADH₂ and thus mitigating electron transfer into the Q-junction not only from succinate in the TCA cycle but from other flavoprotein-catalyzed pathways feeding into the membrane-ETS. This is incorrect as clarified in the next sections.

Complex II and fatty acid oxidation

In the β-oxidation cycle of fatty acid oxidation (FAO), acetyl-CoA and the reducing equivalents FADH₂ and NADH are formed in reactions catalyzed by mt-membrane or matrix

exponential increase of publications with graphical Complex II ambiguities, 2001 to October 2023. Open symbol: the count of 46 publications in 2023 was adjusted for the full year by a multiplication factor of 12/10. Asterisk: zero count in 2004 set at 0.1 for exponential fit. N = 312 is the number of publications found with graphical CII ambiguities (Table 2).




Figure 4. Convergent electron transfer into the NAD junction, ETF junction, and Q-junction indicated by convergent arrows, without showing the alignment of supercomplexes. Inter-membrane space (interM) indicated in grey and mt-matrix in yellow-orange. **A**, convergent FAD-linked electron transfer into the ETF junction as the first step in β -oxidation from very long- and long-chain acyl-CoA dehydrogenases (ACADs, membrane-bound), medium-, and short-chain ACADs including short/branched-ACAD (SBCAD) and Complex I assembly factor ACAD9; in branched-chain amino acid oxidation from glutaryl-CoA DH (GCDH), SBCAD, isobutyryl-CoA DH (IBDH) and isovaleryl-CoA DH (IVDH); in choline metabolism from dimethylglycine DH (DMGDH) and sarcosine DH (SARDH); and from acyl-CoA DH family members 10 and 11 (ACAD10, ACAD11) and D-2-hydroxyglutarate DH (D2HGDH). References (357, 360, 361). ETF is the redox shuttle feeding electrons into the membrane-bound electron transferring flavoprotein Complex (CETFDH on the matrix side of the mtIM) and further into Q. Steps two to four in β -oxidation of long- and medium-chain fatty acids are catalyzed by trifunctional protein (TFP, membrane-bound). Step three reduces NAD^+ to $\text{NADH} + \text{H}^+$, feeding electrons into the NAD-cycle, catalyzed by TFP and short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD). **B**, **N**: N-pathway through Complex I (CI; see Fig. 1). **F**: F-pathway of fatty acid oxidation through the β -oxidation cycle (β -ox) with ACADs binding noncovalently FAD; converging electron transfer through ETF to CETFDH, and dependence on the N-pathway. **S**: S-pathway through CII. **Gp**: Gp-pathway through mt-glycerophosphate DH Complex (CGpDH on the inter-membrane side of the mtIM) oxidizing glycerophosphate to dihydroxyacetone phosphate (DHAP) in the inter-membrane space.

acyl-CoA dehydrogenases (ACADs) and hydroxyacyl-CoA dehydrogenases (HADs), respectively (357). The ACADs are flavoproteins containing FAD/FADH₂ as a prosthetic group (357). The FADH₂ of the ACADs is reoxidized by reducing FAD noncovalently bound to electron-transferring flavoprotein ETF (357–361). Comparable to electron transfer from CIII to CIV by the heme group of cytochrome *c* (362), the small redox protein ETF mediates the transfer of reducing equivalents from FADH₂ of ACADs to the respiratory Complex of the membrane-ETS called electron flavoprotein dehydrogenase ETFDH (360) or electron transfer flavoprotein:ubiquinone oxidoreductase ETF-QO (363). This ETFDH Complex (CETFDH) receives 2{H⁺ + e⁻} from FADH₂ in ETF, linking electron transfer in β -oxidation to electron entry into the Q-junction independent of CII. CETFDH and CI are the respiratory complexes involved in convergent electron entry into the Q-junction during FAO (Fig. 4). In contrast to the membrane-ETS redox shuttle cytochrome *c*, ETF is a matrix-ETS redox shuttle (or a redox shuttle closely associated with the mtIM on its matrix side) where multiple electron transfer pathways converge (Fig. 4A). Thus, the prosthetic group FADH₂ in ETF—or simply ETF—is the substrate of CETFDH, comparable to the substrates succinate for CII, glycerophosphate for the respiratory Complex glycerophosphate dehydrogenase (CGpDH), and NADH for CI at the Q-

junction, or cytochrome *c* for CIV (Fig. 4B). The supercomplex formed between CETFDH and CIII illustrates the CII-independent path of electron transfer from FADH₂ bound to ETF into the Q-junction (360).

When FADH₂ is erroneously shown free floating in the mt-matrix as a substrate of CII, a dubious role of CII in FAO is suggested as a consequence. In Figure 5, A–M, FADH₂ (i) is generated by the TCA cycle and β -oxidation and (ii) donates electrons from a misconstrued “FADH₂ junction” to CII (52, 56, 62, 71, 97, 218, 220, 225, 227, 283, 291, 293, 295, 299); see also (50, 236). In Figure 5N, two alternative pathways of FADH₂ are shown from β -oxidation to CII and CETFDH (83), similar to ref. (84) (Fig. 6) and ref. (201). Picard and colleagues link β -oxidation directly to CII in Figure 5O used in five publications (349, 352–355). In Figure 5P, FADH₂ from the TCA cycle and β -oxidation donates reducing equivalents to the “electron transport chain” (204), where “ETC-specific respiration” is considered to proceed through CI and CII. Compare with refs. (51, 104, 192, 206, 208, 215, 216, 239) (Fig. 5, Q and R). Combined with respiratory Complexes defined as CI, CII, CIII, and CIV in numerical sequence, the concept of a linear ‘electron transport chain’ ETC (in contrast to the convergent ETS) led to the presentation of linear electron flow as (NADH, FADH₂) → CI → CII → CIII ((348); Fig. 5S), with a similar misconception or ambiguity in figures




Figure 5. When FADH₂ is erroneously shown [1] as a substrate of CII, then [2] a dubious role of CII in oxidation of FADH₂ from β-oxidation is suggested as a consequence. Zoom into figures (A) (52); (B) (71); (C) (225); (D) (97); (E) (220); (F) (227); (G) (283, 299); (H) (293); (I) (218); (J) paradoxical oxidation of FADH₂ and NADH in β-oxidation and reduction by CI of NAD⁺ from β-oxidation (56); (K) (295); (L) (62); (M) (291); (N) (83); (O) (349, 352–355); (P) (204); (Q) (192); (R) (51) as in (66); (S) (348); (T) (350); (U) (351).

of refs. (129, 166, 171, 176, 183, 223, 241, 339, 373) (Table 2). Electron transfer is even shown to proceed from fatty acids through ETF to CII (350, 351) (Fig. 5, T and U).

Lemmi *et al* (364) noted: ‘mitochondrial Complex II also participates in the oxidation of fatty acids’. This holds for the oxidation of acetyl-CoA generated in the β-oxidation cycle and oxidized in the TCA cycle, forming NADH and succinate with downstream electron flow through CI and CII, respectively, into the Q-junction (Fig. 1). In contrast, electron transfer from

primary flavin dehydrogenases in β-oxidation proceeds through ETF, which functions as the electron (2{H⁺ + e⁻}) carrier to CETFDH.

FADH₂ reducing equivalents independent of CII: glycerophosphate oxidation and ETF-linked pathways in addition to fatty acid oxidation

Comparable to the display of a putative role of CII in FAO (Fig. 5), the misconstrued pathway from FADH₂ to CII has led to the incorrect notion that CII receives electrons from FADH₂ formed in several branches of the ETS upstream of the Q-junction, particularly in the mitochondrial glycerophosphate DH Complex, CGpDH (59, 84, 90, 345, 365–370). ‘FADH₂ is produced by acyl CoA dehydrogenase (in the β-oxidation cycle), succinate dehydrogenase (in the TCA cycle), and glycerol-3-phosphate dehydrogenase (reoxidation of NADH + H⁺ produced in glycolysis by the glycerol-3-phosphate shuttle). These enzymes form part of the inner mitochondrial membrane in close association with Complex II’ (208). The CII ambiguity (Fig. 6A) misleads to such direct or indirect suggestions that CII in the ETS is positioned downstream of CGpDH (Fig. 6, B–D). For carification, the glyceraldehyde-3-phosphate shuttle (365–370) does not transfer FADH₂ into the mt-matrix (Fig. 6, E and F). There is no “FADH₂ junction” receiving reducing equivalents and feeding electrons downstream into CII (59, 84, 345) (Fig. 6, G–J). The term “FADH₂ linked substrates” (91) is ambiguous and misleading. In convergent electron transfer into the Q-junction, the independent part of CII played in the ETS is clarified by recognition of succinate (but not FADH₂) as the substrate generated in the TCA cycle and feeding 2{H⁺ + e⁻} into the CII-branch of the Q-junction (Fig. 4B).

Conclusions

There is currently ambiguity surrounding the precise role of Complex II in core metabolic pathways of mitochondrial electron transfer, particularly fatty acid oxidation. While Complex II is not essential for fatty acid oxidation, it plays a regulatory role by sensing changes in metabolic demand and activating the TCA cycle for oxidation of acetyl-CoA depending on the metabolic conditions. This regulatory function may be particularly important during periods of low oxygen availability or high energy demand. The integration of FAO with the membrane-bound ETS (360) has significant implications for understanding and treating disorders related to β-oxidation and oxidative phosphorylation.

Do misinformed diagrams—from ambiguous electron transfer to the presentation of CII as an H⁺ pump (303, 341, 371–373) – cast doubts on the quality of the publication? Authors and publishers may enjoy artistic graphs as motivational ornaments rather than informational designs. Whether using iconic or symbolic elements in graphical representations, incorporating complementary text not only enhances the communication of intended meaning but diagrams will be




Figure 6. Ambiguous conclusions on a direct role of CII in the oxidation of glycerophosphate and other “FADH₂-linked” pathways, analogous to false representations of CII involved in fatty acid oxidation (Fig. 5). FADH₂ [1] formed in the mt-matrix as a product of the TCA cycle and [2] feeding into CII: (A) (75); among 312 examples of CII-ambiguities; and FADH₂ [1] formed in the mt-matrix from (B) GPO1 (90), (C) GPD2 (370), and (D) GPDH (365), and [2] feeding into the ETS. GPO1, GPD2, and GPDH indicate the respiratory Complex CGpDH on the inter-membrane side of the mtIM (Fig. 4B). E–G, the glycerol-3-phosphate shuttle is erroneously shown to transfer the redox pair FAD/FADH₂ (not FADH/FADH₂) into the mt-matrix (358, 366, 370). H, the figure (345) suggests that electron transfer into the Q-junction occurs from a common FADH₂ pool generated by CII and CGpDH (GPD2). I and J, The FAD/FADH₂ redox system is implicated in various electron transfer pathways independent of CII, but the CII ambiguity does not make this sufficiently clear (59, 84). FADH₂ must be distinguished as a covalently bound prosthetic group of CII from a coenzyme that is attached loosely and transiently to an enzyme (385).

improved in the process. Using precisely defined terminology prevents misunderstandings (2).

When peer review provides insufficient help for corrections, post-peer review by editors and critical readers is required for

revisions of articles which may be updated and re-published as living communications (374). The present review aims to raise awareness in the scientific community about the inherent ambiguity crisis, complementary to addressing the widely

recognized issues of the reproducibility and credibility crisis (375). The term ‘crisis’ is rooted etymologically in the Greek word *krinein*: meaning to ‘separate, decide, judge’. In this sense, science and communication in general are a continuous crisis at the edge of separating clarity or certainty from confusing double meaning down to fake-news. Reproducibility relates to the condition of repeating and confirming calculations or experiments presented in a published resource. Apart from criticizing established textbooks (376), their acknowledgment with reference to expert bioenergetics reviews (11, 26) and terminological consistency (2) will pave the way out of the CII ambiguity crisis.

As defined in the introduction, the present critical review addresses type 2 ambiguities in redox reactions and bioenergetic pathways involving respiratory Complex II and electron transfer into the Q-junction. In the 312 listed references on CII ambiguities, several figures show H^+ or $2H^+$ being formed in the oxidation of $FADH_2$. The formation of H^+ or $2H^+$ in the oxidation of succinate is displayed in many more references which are not included here. The ambiguous use of the symbol H^+ makes no distinction between (i) $2H^+$ indicating reducing equivalents $2\{H^+ + e^-\}$ participating in oxidoreductases, (ii) H^+ in chemiosmotic translocation across a membrane, and (iii) H^+ in acid/base reactions (Table 2). Several type 2 CII-ambiguities, however, may be more appropriately classified as errors and incorrect representations of scientific facts, resulting from ignorance of the relevant literature. On the other side of the spectrum, we find productive type 1 ambiguities (30), when different points of view lead to innovation. A prominent case of ambiguity in the grey zone between types 1 and 2 has been uniquely demonstrated by analysis of the popular notion of “oxidative stress”—a term more frequently found than “mitochondria” in PubMed-widely used with vague definitions and without expression by numerical values and corresponding units (377). Another example closer to type 2 ambiguity is the use of the terms and experimental application of “hypoxia” and “normoxia” in bioenergetics, when air-level normoxic conditions for isolated mitochondria and cultured cells are effectively hyperoxic and may cause oxidative damage (378, 379). Another ambiguity in bioenergetics links to the confusing use of the terms uncoupling, decoupling, and dyscoupling, where rigorous definitions and distinctions are warranted (2). Linking bioenergetics to physical chemistry and the thermodynamics of irreversible processes, the ambiguous use (type 1) of the terms force and pressure (380–384) has deep consequences on the enigmatic concept of non-ohmic flux-force relationships in the context of mitochondrial membrane potential and the protonmotive force (6).

The present review adds Complex II ambiguities to the growing list. The trust in the science of bioenergetics is at stake — the trust of students, the general public, granting agencies, and stakeholders in the research-based health system. Clarification instead of the perpetuation of Complex II ambiguities leads to a better representation of fundamental concepts of bioenergetics and helps to maintain the high scientific standards required for translating

knowledge on metabolism into clinical solutions for mitochondrial diseases.

Acknowledgments—I thank Luiza H Cardoso, Sabine Schmitt, and Chris Donnelly for stimulating discussions, and Paolo Cocco for expert help on the graphical abstract and Figure 1, D and E. The constructive comments of an anonymous reviewer (J Biol Chem.) are explicitly acknowledged. Contribution to the European Union’s Horizon 2020 research and innovation program Grant 857394 (FAT4BRAIN).

Conflict of interest—E. Gnaiger is editor-in-chief of *Bioenergetics Communications*.

Abbreviations—The abbreviations used are: $2\{H^+ + e^-\}$, redox equivalents in H^+ -linked electron transfer; CI, Complex I; CII, Complex II, SDH; CETFDH, electron transferring flavoprotein dehydrogenase Complex; CGpDH, mt-glycerophosphate dehydrogenase Complex; DH, dehydrogenase; FAD, oxidized flavin adenine dinucleotide; $FADH_2$, reduced flavin adenine dinucleotide; FAO, fatty acid oxidation; FMN, oxidized flavin mononucleotide; $FMNH_2$, reduced flavin mononucleotide; mt-matrix, mitochondrial matrix; mtIM, mitochondrial inner membrane; NAD, nicotinamide adenine dinucleotide, oxidation state is not implied; NAD^+ , oxidized nicotinamide adenine dinucleotide; $NADH_2$, reduced nicotinamide adenine dinucleotide; Q, ETS-reactive coenzyme Q, oxidation state is not implied; QFR, mena-quinol-fumarate oxidoreductase; SQR, succinate-ubiquinone oxidoreductase; SDH, succinate dehydrogenase, CII; TCA cycle, tricarboxylic acid cycle.

References

- Krebs, H. A., and Eggleston, L. V. (1940) The oxidation of pyruvate in pigeon breast muscle. *Biochem. J.* **34**, 442–459
- Gnaiger, E., Eleonor, A. F., Norwahidah, A. K., Ali, A. R., Abumrad Nada, A., Acuna-Castroviejo, D., et al. (2020) MitoEAGLE Task Group. Mitochondrial physiology. *Bioenerg. Commun.* **1**, 1–44
- Bénil, P., Goncalves, J., El Khoury, R., Rak, M., Favier, J., Gimenez-Roqueplo, A. P., et al. (2022) Succinate dehydrogenase, succinate, and superoxides: a genetic, epigenetic, metabolic, environmental explosive crossroad. *Biomedicines* **10**, 1788
- Arnold, P. K., and Finley, L. W. S. (2023) Regulation and function of the mammalian tricarboxylic acid cycle. *J. Biol. Chem.* **299**, 102838
- Murphy, M. P., and O’Neill, L. A. J. (2018) Krebs cycle reimaged: the emerging roles of succinate and itaconate as signal transducers. *Cell* **174**, 780–784
- Gnaiger, E. (2020) Mitochondrial pathways and respiratory control. An introduction to OXPHOS analysis. 5th ed. *Bioenerg. Commun.* <https://doi.org/10.26124/bec:2020-0002>
- Hatefi, Y. (1985) The mitochondrial electron transport and oxidative phosphorylation system. *Annu. Rev. Biochem.* **54**, 1015–1069
- Thunberg, T. (1909) Studien über die Beeinflussung des Gasaustausches des überlebenden Froschmuskels durch verschiedene Stoffe. *Skand Arch. Physiol.* **22**, 430–436
- Huang, S., Braun, H. P., Gawryluk, R. M. R., and Millar, A. H. (2019) Mitochondrial complex II of plants: subunit composition, assembly, and function in respiration and signaling. *Plant J.* **98**, 405–417
- Moosavi, B., Berry, E. A., Zhu, X. L., Yang, W. C., and Yang, G. F. (2019) The assembly of succinate dehydrogenase: a key enzyme in bioenergetics. *Cell Mol. Life Sci.* **76**, 4023–4042
- Cecchini, G. (2003) Function and structure of Complex II of the respiratory chain. *Annu. Rev. Biochem.* **72**, 77–109
- Iverson, T. M. (2013) Catalytic mechanisms of complex II enzymes: a structural perspective. *Biochim. Biophys. Acta* **1827**, 648–657

13. Maklashina, E., Iverson, T. M., and Cecchini, G. (2022) How an assembly factor enhances covalent FAD attachment to the flavoprotein subunit of complex II. *J. Biol. Chem.* **298**, 102472
14. Hochachka, P. W., and Somero, G. N. (2002) *Biochemical Adaptation: Mechanism and Process in Physiological Evolution*, Oxford Univ Press, New York
15. Müller, M., Mentel, M., van Hellemond, J. J., Henze, K., Woehle, C., Gould, S. B., *et al.* (2012) Biochemistry and evolution of anaerobic energy metabolism in eukaryotes. *Microbiol. Mol. Biol. Rev.* **76**, 444–495
16. Gnaiger, E. (1993) Efficiency and power strategies under hypoxia. Is low efficiency at high glycolytic ATP production a paradox? In: Hochachka, P. W., Lutz, P. L., Sick, T., Rosenthal, M., Van den Thillart, G., eds. *Surviving Hypoxia: Mechanisms of Control and Adaptation*, CRC Press, Boca Raton, Ann Arbor, London, Tokyo: 77–109
17. Tretter, L., Patocs, A., and Chinopoulos, C. (2016) Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. *Biochim. Biophys. Acta* **1857**, 1086–1101
18. Robb, E. L., Hall, A. R., Prime, T. A., Eaton, S., Szibor, M., Viscomi, C., *et al.* (2018) Control of mitochondrial superoxide production by reverse electron transport at complex I. *J. Biol. Chem.* **293**, 9869–9879
19. Spinelli, J. B., Rosen, P. C., Sprenger, H. G., Puszyńska, A. M., Mann, J. L., Roessler, J. M., *et al.* (2021) Fumarate is a terminal electron acceptor in the mammalian electron transport chain. *Science* **374**, 1227–1237
20. Chouchani, E. T., Pell, V. R., Gaude, E., Aksentijević, D., Sundier, S. Y., Robb, E. L., *et al.* (2014) Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. *Nature* **515**, 431–435
21. Smith, E., and Morowitz, H. J. (2004) Universality in intermediary metabolism. *Proc. Natl. Acad. Sci. U. S. A.* **101**, 13168–13173
22. Lane, N. (2022) *Transformer: The Deep Chemistry of Life and Death*. Profile Books, London, UK
23. DeBerardinis, R. J., and Chandel, N. S. (2016) Fundamentals of cancer metabolism. *Sci. Adv.* **2**, e1600200
24. Schöpf, B., Weissensteiner, H., Schäfer, G., Fazzini, F., Charoentong, P., Naschberger, A., *et al.* (2020) OXPHOS remodeling in high-grade prostate cancer involves mtDNA mutations and increased succinate oxidation. *Nat. Commun.* **11**, 1487
25. Murphy, M. P., and Chouchani, E. T. (2022) Why succinate? Physiological regulation by a mitochondrial coenzyme Q sentinel. *Nat. Chem. Biol.* **18**, 461–469
26. Iverson, T. M., Singh, P. K., and Cecchini, G. (2023) An evolving view of Complex II – non-canonical complexes, megacomplexes, respiration, signaling, and beyond. *J. Biol. Chem.* **299**, 104761
27. Atallah, R., Olschewski, A., and Heinemann, A. (2022) Succinate at the crossroad of metabolism and angiogenesis: roles of SDH, HIF1 α and SUCNR1. *Biomedicines* **10**, 3089
28. Bandara, A. B., Drake, J. C., and Brown, D. A. (2021) Complex II subunit SDHD is critical for cell growth and metabolism, which can be partially restored with a synthetic ubiquinone analog. *BMC Mol. Cell Biol.* **22**, 35
29. Goetzman, E., Gong, Z., Zhang, B., and Muzumdar, R. (2023) Complex II biology in aging, health, and disease. *Antioxidants (Basel)*. **12**, 1477
30. Grosholz, E. R. (2007) *Representation and Productive Ambiguity in Mathematics and the Sciences*. Oxford University Press, Oxford, UK: 312
31. Komlódi, T., Cardoso, L. H. D., Doerrier, C., Moore, A. L., Rich, P. R., and Gnaiger, E. (2021) Coupling and pathway control of coenzyme Q redox state and respiration in isolated mitochondria. *Bioenerg. Commun.* **2021**, 3
32. Hatefi, Y., Haavik, A. G., Fowler, L. R., and Griffiths, D. E. (1962) Studies on the electron transfer system XLII. Reconstitution of the electron transfer system. *J. Biol. Chem.* **237**, 2661–2669
33. Banerjee, R., Purhonen, J., and Kallijärvi, J. (2022) The mitochondrial coenzyme Q junction and Complex III: biochemistry and pathophysiology. *FEBS J.* **289**, 6936–6958
34. Pallag, G., Nazarian, S., Ravasz, D., Bui, D., Komlódi, T., Doerrier, C., *et al.* (2022) Proline oxidation supports mitochondrial ATP production when Complex I is inhibited. *Int. J. Mol. Sci.* **23**, 5111
35. Kearney, E. B. (1960) Studies on succinic dehydrogenase. XII. Flavin component of the mammalian enzyme. *J. Biol. Chem.* **235**, 865–877
36. Lehninger, A. L. (1975) *Biochemistry. The Molecular Basis of Cell Structure and Function*, 2nd edition, Worth Publishers, New York: 1104
37. Tzagoloff, A. (1982) *Mitochondria*. Plenum Press, New York: 342
38. Vercellino, I., and Sazanov, L. A. (2022) The assembly, regulation and function of the mitochondrial respiratory chain. *Nat. Rev. Mol. Cell Biol.* **23**, 141–161
39. Du, Z., Zhou, X., Lai, Y., Xu, J., Zhang, Y., Zhou, S., *et al.* (2023) Structure of the human respiratory complex II. *Proc. Natl. Acad. Sci. U. S. A.* **120**, e2216713120
40. Karavaeva, V., and Sousa, F. L. (2023) Modular structure of complex II: an evolutionary perspective. *Biochim. Biophys. Acta Bioenerg.* **1864**, 148916
41. Mills, E. L., Pierce, K. A., Jedrychowski, M. P., Garrity, R., Winther, S., Vidoni, S., *et al.* (2018) Accumulation of succinate controls activation of adipose tissue thermogenesis. *Nature* **560**, 102–106
42. Fink, B. D., Rauckhorst, A. J., Taylor, E. B., Yu, L., and Sivitz, W. I. (2022) Membrane potential-dependent regulation of mitochondrial complex II by oxaloacetate in interscapular brown adipose tissue. *FASEB Bioadv.* **4**, 197–210
43. Hsu, C. P., Hammarström, L., and Newton, M. D. (2022) 65 years of electron transfer. *J. Chem. Phys.* **157**, 020401
44. Bunnett, J. F., and Jones, R. A. Y. (1988) Names for hydrogen atoms, ions, and groups, and for reactions involving them. *Pure Appl. Chem.* **60**, 1115–1116
45. Cooper, G. M. (2000) *The Cell: A Molecular Approach*, 2nd edition, Sinauer Associates, Sunderland (MA)
46. Gnaiger, E. (1993) Nonequilibrium thermodynamics of energy transformations. *Pure Appl. Chem.* **65**, 1983–2002
47. Wardle, C. (2023) Misunderstanding misinformation. *Issues Sci. Technol.* **39**, 38–40
48. Alzaid, F., Patel, V. B., and Preedy, V. R. (2015) Biomarkers of oxidative stress in blood. In: Preedy, V., Patel, V. R., eds. *General Methods in Biomarker Research and Their Applications. Biomarkers in Disease: Methods, Discoveries and Applications*, Springer, Dordrecht. https://doi.org/10.1007/978-94-007-7696-8_41
49. Aye, I. L. M. H., Aiken, C. E., Charnock-Jones, D. S., and Smith, G. C. S. (2022) Placental energy metabolism in health and disease-significance of development and implications for preeclampsia. *Am. J. Obstet. Gynecol.* **226**, S928–S944
50. Balasubramaniam, S., and Yapito-Lee, J. (2020) Riboflavin metabolism: role in mitochondrial function. *J. Transl. Genet. Genom.* **4**, 285–306
51. Begriche, K., Massart, J., Robin, M. A., Borgne-Sanchez, A., and Fromenty, B. (2011) Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver. *J. Hepatol.* **54**, 773–794
52. Beier, U. H., Angelin, A., Akimova, T., Wang, L., Liu, Y., Xiao, H., *et al.* (2015) Essential role of mitochondrial energy metabolism in Foxp3⁺ T-regulatory cell function and allograft survival. *FASEB J.* **29**, 2315–2326
53. Begum, H. M., and Shen, K. (2023) Intracellular and microenvironmental regulation of mitochondrial membrane potential in cancer cells. *Wires Mech. Dis.* **15**, e1595
54. Bhargava, P., and Schnellmann, R. G. (2017) Mitochondrial energetics in the kidney. *Nat. Rev. Nephrol.* **13**, 629–646
55. Boukalova, S., Hubackova, S., Milosevic, M., Ezrova, Z., Neuzil, J., and Rohlena, J. (2020) Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer. *Biochim. Biophys. Acta Mol. Basis Dis.* **1866**, 165759
56. Camara, A. K., Bienengraeber, M., and Stowe, D. F. (2011) Mitochondrial approaches to protect against cardiac ischemia and reperfusion injury. *Front. Physiol.* **2**, 13
57. Chakrabarty, R. P., and Chandel, N. S. (2021) Mitochondria as signaling organelles control mammalian stem cell fate. *Cell Stem Cell* **28**, 394–408
58. Chandel, N. S. (2021) Mitochondria. *Cold Spring Harb. Perspect. Biol.* **13**, a040543
59. Cogliati, S., Cabrera-Alarcón, J. L., and Enriquez, J. A. (2021) Regulation and functional role of the electron transport chain supercomplexes. *Biochem. Soc. Trans.* **49**, 2655–2668
60. de Beauchamp, L., Himonas, E., and Helgason, G. V. (2022) Mitochondrial metabolism as a potential therapeutic target in myeloid leukaemia. *Leukemia* **36**, 1–12

61. [preprint] Du, J., Sudlow, L. C., Shahverdi, K., Zhou, H., Michie, M., Schindler, T. H., *et al.* (2023) Oxaliplatin-induced cardiotoxicity in mice is connected to the changes in energy metabolism in the heart tissue. *bioRxiv*. <https://doi.org/10.1101/2023.05.24.542198>
62. Esparza-Moltó, P. B., and Cuezva, J. M. (2020) Reprogramming oxidative phosphorylation in cancer: a role for RNA-binding proteins. *Antioxid. Redox Signal.* **33**, 927–945
63. Ezeani, M. (2020) Aberrant cardiac metabolism leads to cardiac arrhythmia. *Front. Biosci. (Schol Ed.)* **12**, 200–221
64. Fahlbusch, P., Nikolic, A., Hartwig, S., Jacob, S., Kettel, U., Köllmer, C., *et al.* (2022) Adaptation of oxidative phosphorylation machinery compensates for hepatic lipotoxicity in early stages of MAFLD. *Int. J. Mol. Sci.* **23**, 6873
65. Fink, B. D., Bai, F., Yu, L., Sheldon, R. D., Sharma, A., Taylor, E. B., *et al.* (2018) Oxaloacetic acid mediates ADP-dependent inhibition of mitochondrial complex II-driven respiration. *J. Biol. Chem.* **293**, 19932–19941
66. Fromenty, B., and Roden, M. (2023) Mitochondrial alterations in fatty liver diseases. *J. Hepatol.* **78**, 415–429
67. Gammon, S. T., Pisaneschi, F., Bandi, M. L., Smith, M. G., Sun, Y., Rao, Y., *et al.* (2019) Mechanism-specific pharmacodynamics of a novel Complex-I inhibitor quantified by imaging reversal of consumptive hypoxia with [¹⁸F]FAZA PET *in vivo*. *Cells* **8**, 1487
68. Goetzman, E. S. (2011) Modeling disorders of fatty acid metabolism in the mouse. *Prog. Mol. Biol. Transl. Sci.* **100**, 389–417
69. Hamanaka, R. B., and Chandel, N. S. (2013) Mitochondrial metabolism as a regulator of keratinocyte differentiation. *Cell Logist.* **3**, e25456
70. Han, S., and Chandel, N. S. (2021) Lessons from cancer metabolism for pulmonary arterial hypertension and fibrosis. *Am. J. Respir. Cell Mol. Biol.* **65**, 134–145
71. Hinder, L. M., Sas, K. M., O'Brien, P. D., Backus, C., Kayampilly, P., Hayes, J. M., *et al.* (2019) Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes. *Sci. Rep.* **9**, 881
72. Iakovou, E., and Kourti, M. (2022) A comprehensive overview of the complex role of oxidative stress in aging, the contributing environmental stressors and emerging antioxidant therapeutic interventions. *Front. Aging Neurosci.* **14**, 827900
73. Intlekofer, A. M., and Finley, L. W. S. (2019) Metabolic signatures of cancer cells and stem cells. *Nat. Metab.* **1**, 177–188
74. Jaramillo-Jimenez, A., Gil, L. M., Borda, M. G., Tovar-Rios, D. A., Kristiansen, K. A., Bruheim, P., *et al.* (2023) Serum TCA cycle metabolites in Lewy bodies dementia and Alzheimer's disease: network analysis and cognitive prognosis. *Mitochondrion* **71**, 17–25
75. Koopman, M., Michels, H., Dancy, B. M., Kamble, R., Mouchiroud, L., Auwerx, J., *et al.* (2016) A screening-based platform for the assessment of cellular respiration in *Caenorhabditis elegans*. *Nat. Protoc.* **11**, 1798–1816
76. Liufu, T., Yu, H., Yu, J., Yu, M., Tian, Y., Ou, Y., *et al.* (2023) Complex I deficiency in m.3243A>G fibroblasts is alleviated by reducing NADH accumulation. *Front. Physiol.* **14**, 1164287
77. Luo, X., Li, R., and Yan, L. J. (2015) Roles of pyruvate, NADH, and mitochondrial Complex I in redox balance and imbalance in β cell function and dysfunction. *J. Diabetes Res.* **2015**, 512618
78. Madamanchi, N. R., and Runge, M. S. (2007) Mitochondrial dysfunction in atherosclerosis. *Circ. Res.* **100**, 460–473
79. Martínez-Reyes, I., Cardona, L. R., Kong, H., Vasani, K., McElroy, G. S., Werner, M., *et al.* (2020) Mitochondrial ubiquinol oxidation is necessary for tumour growth. *Nature* **585**, 288–292
80. Martínez-Reyes, I., and Chandel, N. S. (2020) Mitochondrial TCA cycle metabolites control physiology and disease. *Nat. Commun.* **11**, 102
81. Massart, J., Begriche, K., Buron, N., Porceddu, M., Borgne-Sanchez, A., and Fromenty, B. (2013) Drug-induced inhibition of mitochondrial fatty acid oxidation and steatosis. *Curr. Pathobiol. Rep.* **1**, 147–157
82. Massoz, S., Cardol, P., González-Halphen, D., and Remacle, C. (2017) Mitochondrial bioenergetics pathways in *Chlamydomonas*. In: Hippler, M., ed., *Chlamydomonas: Molecular Genetics and Physiology* **30**. Springer, Cham: 59–95. https://doi.org/10.1007/978-3-319-66365-4_3
83. Missaglia, S., Taviani, D., and Angelini, C. (2021) ETF dehydrogenase advances in molecular genetics and impact on treatment. *Crit. Rev. Biochem. Mol. Biol.* **56**, 360–372
84. Mosegaard, S., Dipace, G., Bross, P., Carlsen, J., Gregersen, N., and Olsen, R. K. J. (2020) Riboflavin deficiency-implications for general human health and inborn errors of metabolism. *Int. J. Mol. Sci.* **21**, 3847
85. Nolfi-Donegan, D., Braganza, A., and Shiva, S. (2020) Mitochondrial electron transport chain: oxidative phosphorylation, oxidant production, and methods of measurement. *Redox Biol.* **37**, 101674
86. Nsiah-Sefaa, A., and McKenzie, M. (2016) Combined defects in oxidative phosphorylation and fatty acid β -oxidation in mitochondrial disease. *Biosci. Rep.* **36**, e00313
87. Pelletier-Galarneau, M., Detmer, F. J., Petibon, Y., Normandin, M., Ma, C., Alpert, N. M., *et al.* (2021) Quantification of myocardial mitochondrial membrane potential using PET. *Curr. Cardiol. Rep.* **23**, 70
88. Peng, M., Huang, Y., Zhang, L., Zhao, X., and Hou, Y. (2022) Targeting mitochondrial oxidative phosphorylation eradicates acute myeloid leukemic stem cells. *Front. Oncol.* **12**, 899502
89. Protti, A., and Singer, M. (2006) Bench-to-bedside review: potential strategies to protect or reverse mitochondrial dysfunction in sepsis-induced organ failure. *Crit. Care* **10**, 228
90. Rai, M., Carter, S. M., Shefali, S. A., Mahmouzdadeh, N. H., Pepin, R., and Tennessen, J. M. (2022) The *Drosophila melanogaster* enzyme glycerol-3-phosphate dehydrogenase 1 is required for oogenesis, embryonic development, and amino acid homeostasis. *G3 (Bethesda)* **12**, jkac115
91. Sadri, S., Tomar, N., Yang, C., Audi, S. H., Cowley, A. W., Jr., and Dash, R. K. (2023) Effects of ROS pathway inhibitors and NADH and FADH₂ linked substrates on mitochondrial bioenergetics and ROS emission in the heart and kidney cortex and outer medulla. *Arch. Biochem. Biophys.* **744**, 109690
92. Sanchez, H., Zoll, J., Bigard, X., Veksler, V., Mettauer, B., Lampert, E., *et al.* (2001) Effect of cyclosporin A and its vehicle on cardiac and skeletal muscle mitochondria: relationship to efficacy of the respiratory chain. *Br. J. Pharmacol.* **133**, 781–788
93. Scandella, V., Petrelli, F., Moore, D. L., Braun, S. M. G., and Knobloch, M. (2023) Neural stem cell metabolism revisited: a critical role for mitochondria. *Trends Endocrinol. Metab.* **34**, 446–461
94. Schwartz, B., Gjini, P., Gopal, D. M., and Fetterman, J. L. (2022) Inefficient batteries in heart failure: metabolic bottlenecks disrupting the mitochondrial ecosystem. *JACC Basic Transl. Sci.* **7**, 1161–1179
95. Shen, Y. A., Chen, C. C., Chen, B. J., Wu, Y. T., Juan, J. R., Chen, L. Y., *et al.* (2021) Potential therapies targeting metabolic pathways in cancer stem cells. *Cells* **10**, 1772
96. Shinmura, K. (2013) Effects of caloric restriction on cardiac oxidative stress and mitochondrial bioenergetics: potential role of cardiac sirtuins. *Oxid. Med. Cell Longev.* **2013**, 528935
97. Toleikis, A., Trumbeckaite, S., Liobikas, J., Pauziene, N., Kursvietiene, L., and Kopustinskiene, D. M. (2020) Fatty acid oxidation and mitochondrial morphology changes as key modulators of the affinity for ADP in rat heart mitochondria. *Cells* **9**, 340
98. Wilson, N., Kataura, T., Korsgen, M. E., Sun, C., Sarkar, S., and Korolchuk, V. I. (2023) The autophagy-NAD axis in longevity and disease. *Trends Cell Biol.* **33**, 788–802
99. Yusoff, A. A. M., Ahmad, F., Idris, Z., Jaafar, H., and Abdullah, J. M. (2015) Understanding mitochondrial DNA in brain tumorigenesis. In: Lichtor, T., ed. *Molecular Considerations and Evolving Surgical Management Issues in the Treatment of Patients with a Brain Tumor*, InTech, London, UK
100. Arden, G. B., and Ramsey, D. J. (2015) Diabetic retinopathy and a novel treatment based on the biophysics of rod photoreceptors and dark adaptation. In: Kolb, H., Fernandez, E., Nelson, R., eds. *Webvision: The Organization of the Retina and Visual System*, University of Utah Health Sciences Center, Salt Lake City (UT)
101. Bao, M. H., and Wong, C. C. (2021) Hypoxia, metabolic reprogramming, and drug resistance in liver cancer. *Cells* **10**, 1715
102. Bayona-Bafaluy, M. P., Garrido-Pérez, N., Meade, P., Iglesias, E., Jiménez-Salvador, I., Montoya, J., *et al.* (2021) Down syndrome is an oxidative phosphorylation disorder. *Redox Biol.* **41**, 101871

103. Bellance, N., Lestienne, P., and Rossignol, R. (2009) Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. *Front. Biosci. (Landmark Ed.)* **14**, 4015–4034
104. Benard, G., Bellance, N., Jose, C., and Rossignol, R. (2011) Relationships between mitochondrial dynamics and bioenergetics. In: Lu, B., ed. *Mitochondrial Dynamics and Neurodegeneration*, Springer, New York, NY: 47–68
105. Bernardo, A., De Simone, R., De Nuccio, C., Visentin, S., and Minghetti, L. (2013) The nuclear receptor peroxisome proliferator-activated receptor- γ promotes oligodendrocyte differentiation through mechanisms involving mitochondria and oscillatory Ca^{2+} waves. *Biol. Chem.* **394**, 1607–1614
106. Bețiu, A. M., Noveanu, L., Hâncu, I. M., Lascu, A., Petrescu, L., Maack, C., et al. (2022) Mitochondrial effects of common cardiovascular medications: the good, the bad and the mixed. *Int. J. Mol. Sci.* **23**, 13653
107. Beutner, G., Eliseev, R. A., and Porter, G. A., Jr. (2014) Initiation of electron transport chain activity in the embryonic heart coincides with the activation of mitochondrial complex I and the formation of super-complexes. *PLoS One* **9**, e113330
108. Bhalerao, S., and Clandinin, T. R. (2012) Vitamin K₂ takes charge. *Science* **336**, 1241–1242
109. Billingham, L. K., Stoolman, J. S., Vasani, K., Rodriguez, A. E., Poor, T. A., Szibor, M., et al. (2022) Mitochondrial electron transport chain is necessary for NLRP3 inflammasome activation. *Nat. Immunol.* **23**, 692–704
110. Brownlee, M. (2001) Biochemistry and molecular cell biology of diabetic complications. *Nature* **414**, 813–820
111. Brownlee, M. (2003) A radical explanation for glucose-induced beta cell dysfunction. *J. Clin. Invest.* **112**, 1788–1790
112. Choudhury, F. K. (2021) Mitochondrial redox metabolism: the epicenter of metabolism during cancer progression. *Antioxidants (Basel)* **10**, 1838
113. de Villiers, D., Potgieter, M., Ambele, M. A., Adam, L., Durandt, C., and Pepper, M. S. (2018) The role of reactive oxygen species in adipogenic differentiation. *Adv. Exp. Med. Biol.* **1083**, 125–144
114. Delpont, A., Harvey, B. H., Petzer, A., and Petzer, J. P. (2017) Methylene blue and its analogues as antidepressant compounds. *Metab. Brain Dis.* **32**, 1357–1382
115. Ekbal, N. J., Dyson, A., Black, C., and Singer, M. (2013) Monitoring tissue perfusion, oxygenation, and metabolism in critically ill patients. *Chest* **143**, 1799–1808
116. Escoll, P., Platon, L., and Buchrieser, C. (2019) Roles of mitochondrial respiratory complexes during infection. *Immunometabolism* **1**, e190011
117. Eyenga, P., Rey, B., Eyenga, L., and Sheu, S. S. (2022) Regulation of oxidative phosphorylation of liver mitochondria in sepsis. *Cells* **11**, 1598
118. Favia, M., de Bari, L., Bobba, A., and Atlante, A. (2019) An intriguing involvement of mitochondria in cystic fibrosis. *J. Clin. Med.* **8**, 1890
119. Feher, J. (2017) 2.10 - ATP production II: the TCA cycle and oxidative phosphorylation. In: *Quantitative Human Physiology*, 2nd ed, Academic Press, Boston
120. Garcia-Neto, W., Cabrera-Orefice, A., Uribe-Carvajal, S., Kowaltowski, A. J., and Luévano-Martínez, L. A. (2017) High osmolarity environments activate the mitochondrial alternative oxidase in *Debaryomyces Hansenii*. *PLoS One* **12**, e0169621
121. Garrido-Pérez, N., Vela-Sebastián, A., López-Gallardo, E., Emperador, S., Iglesias, E., Meade, P., et al. (2020) Oxidative phosphorylation dysfunction modifies the cell secretome. *Int. J. Mol. Sci.* **21**, 3374
122. Gasmí, A., Peana, M., Arshad, M., Butnariu, M., Menzel, A., and Björklund, G. (2021) Krebs cycle: activators, inhibitors and their roles in the modulation of carcinogenesis. *Arch. Toxicol.* **95**, 1161–1178
123. Geng, Y., Hu, Y., Zhang, F., Tuo, Y., Ge, R., and Bai, Z. (2023) Mitochondria in hypoxic pulmonary hypertension, roles and the potential targets. *Front. Physiol.* **14**, 1239643
124. Giachin, G., Jessop, M., Bouverot, R., Acajjaoui, S., Saïdi, M., Chretien, A., et al. (2021) Assembly of the mitochondrial Complex I assembly complex suggests a regulatory role for deamination. *Angew. Chem. Int. Ed. Engl.* **60**, 4689–4697
125. Gopan, A., and Sarma, M. S. (2021) Mitochondrial hepatopathy: respiratory chain disorders- 'breathing in and out of the liver. *World J. Hepatol.* **13**, 1707–1726
126. Gujarati, N. A., Vasquez, J. M., Bogenhagen, D. F., and Mallipattu, S. K. (2020) The complicated role of mitochondria in the podocyte. *Am. J. Physiol. Ren. Physiol.* **319**, F955–F965
127. Han, S., and Chandel, N. S. (2019) There is no smoke without mitochondria. *Am. J. Respir. Cell Mol. Biol.* **60**, 489–491
128. Hanna, D., Kumar, R., and Banerjee, R. (2023) A metabolic paradigm for hydrogen sulfide signaling via electron transport chain plasticity. *Antioxid. Redox Signal.* **38**, 57–67
129. Hanna, J., David, L. A., Touahri, Y., Fleming, T., Scream, R. A., and Schuurmans, C. (2022) Beyond genetics: the role of metabolism in photoreceptor survival, development and repair. *Front. Cell Dev. Biol.* **10**, 887764
130. Howie, D., Waldmann, H., and Cobbold, S. (2014) Nutrient sensing via mTOR in T cells maintains a tolerogenic microenvironment. *Front. Immunol.* **5**, 409
131. Jarmuszkiewicz, W., Dominiak, K., Budzinska, A., Wojcicki, K., and Galganski, L. (2023) Mitochondrial coenzyme Q redox homeostasis and reactive oxygen species production. *Front. Biosci. (Landmark Ed.)* **28**, 61
132. Javali, P. S., Sekar, M., Kumar, A., and Thirumurugan, K. (2023) Dynamics of redox signaling in aging via autophagy, inflammation, and senescence. *Biogerontology* **24**, 663–678
133. Jayasankar, V., Vrdoljak, N., Roma, A., Ahmed, N., Tcheng, M., Minden, M. D., et al. (2022) Novel mango ginger bioactive (2,4,6-trihydroxy-3,5-diprenyldihydrochalcone) inhibits mitochondrial metabolism in combination with Avocatin B. *ACS Omega* **7**, 1682–1693
134. Keane, P. C., Kurzawa, M., Blain, P. G., and Morris, C. M. (2011) Mitochondrial dysfunction in Parkinson's disease. *Parkinsons Dis.* **2011**, 716871
135. Kim, E. H., Koh, E. H., Park, J. Y., and Lee, K. U. (2010) Adenine nucleotide translocator as a regulator of mitochondrial function: implication in the pathogenesis of metabolic syndrome. *Korean Diabetes J.* **34**, 146–153
136. Knottnerus, S. J. G., Bleeker, J. C., Wüst, R. C. I., Ferdinandusse, S., Ijlst, L., Wijburg, F. A., et al. (2018) Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. *Rev. Endocr. Metab. Disord.* **19**, 93–106
137. Kumar, R., Landry, A. P., Guha, A., Vitvitsky, V., Lee, H. J., Seike, K., et al. (2021) A redox cycle with complex II prioritizes sulfide quinone oxidoreductase dependent H₂S oxidation. *J. Biol. Chem.* **298**, 101435
138. Ley-Ngardigal, S., and Bertolin, G. (2022) Approaches to monitor ATP levels in living cells: where do we stand? *FEBS J.* **289**, 7940–7969
139. Litwack, G. (2018) Metabolism of fat, carbohydrate, and nucleic acids, Chapter 14. In: Litwack, G., ed. *Human Biochemistry*, Academic Press, Cambridge, MA: 395–426
140. Litwiniuk, A., Baranowska-Bik, A., Domańska, A., Kalisz, M., and Bik, W. (2021) Contribution of mitochondrial dysfunction combined with NLRP3 inflammasome activation in selected neurodegenerative diseases. *Pharmaceuticals (Basel)* **14**, 1221
141. Liu, Y., Sun, Y., Guo, Y., Shi, X., Chen, X., Feng, W., et al. (2023) An overview: the diversified role of mitochondria in cancer metabolism. *Int. J. Biol. Sci.* **19**, 897–915
142. Lozano, O., Lázaro-Alfaro, A., Silva-Platas, C., Oropeza-Almazán, Y., Torres-Quintanilla, A., Bernal-Ramírez, J., et al. (2019) Nano-encapsulated quercetin improves cardioprotection during hypoxia-reoxygenation injury through preservation of mitochondrial function. *Oxid. Med. Cell Longev.* **2019**, 7683051
143. Luo, Y., Ma, J., and Lu, W. (2020) The significance of mitochondrial dysfunction in cancer. *Int. J. Mol. Sci.* **21**, 5598
144. Ma, Z. A., Zhao, Z., and Turk, J. (2012) Mitochondrial dysfunction and β -cell failure in type 2 diabetes mellitus. *Exp. Diabetes Res.* **2012**, 703538
145. Maffezzini, C., Calvo-Garrido, J., Wredenberg, A., and Freyer, C. (2020) Metabolic regulation of neurodifferentiation in the adult brain. *Cell Mol. Life Sci.* **77**, 2483–2496
146. Mantle, D., Heaton, R. A., and Hargreaves, I. P. (2021) Coenzyme Q₁₀, ageing and the nervous system: an overview. *Antioxidants (Basel)* **11**, 2
147. Martínez-Reyes, I., Diebold, L. P., Kong, H., Schieber, M., Huang, H., Hensley, C. T., et al. (2016) TCA cycle and mitochondrial membrane potential are necessary for diverse biological functions. *Mol. Cell* **61**, 199–209

148. Mathiyazakan, V., Wong, C. F., Harikishore, A., Pethe, K., and Grüber, G. (2023) Cryo-electron microscopy structure of the *Mycobacterium tuberculosis* cytochrome *bcc:aa3* supercomplex and a novel inhibitor targeting subunit cytochrome *cl*. *Antimicrob. Agents Chemother.* **67**, e0153122
149. Mathur, D., Riffo-Campos, A. L., Castillo, J., Haines, J. D., Vidaurre, O. G., Zhang, F., *et al.* (2017) Bioenergetic failure in rat oligodendrocyte progenitor cells treated with cerebrospinal fluid derived from multiple sclerosis patients. *Front. Cell Neurosci.* **11**, 209
150. McCollum, C., Geißelsöder, S., Engelsdorf, T., Voitsik, A. M., and Voll, L. M. (2019) Deficiencies in the mitochondrial electron transport chain affect redox poise and resistance toward *Colletotrichum higginsianum*. *Front. Plant Sci.* **10**, 1262
151. McElroy, G. S., and Chandel, N. S. (2017) Mitochondria control acute and chronic responses to hypoxia. *Exp. Cell Res.* **356**, 217–222
152. McElroy, G. S., Reczek, C. R., Reyfman, P. A., Mithal, D. S., Horbinski, C. M., and Chandel, N. S. (2020) NAD⁺ regeneration rescues lifespan, but not ataxia, in a mouse model of brain mitochondrial Complex I dysfunction. *Cell Metab.* **32**, 301–308.e6
153. Morelli, A. M., Ravera, S., Calzia, D., and Panfoli, I. (2019) An update of the chemiosmotic theory as suggested by possible proton currents inside the coupling membrane. *Open Biol.* **9**, 180221
154. Narine, M., and Colognato, H. (2022) Current insights into oligodendrocyte metabolism and its power to sculpt the myelin landscape. *Front. Cell Neurosci.* **16**, 892968
155. Paprocka, J., Nowak, M., Chuchra, P., and Śmigiel, R. (2022) COQ8A-ataxia as a manifestation of primary coenzyme Q deficiency. *Metabolites* **12**, 955
156. Peña-Corona, S. I., Hernández-Parra, H., Bernal-Chávez, S. A., Mendoza-Muñoz, N., Romero-Montero, A., Del Prado-Audelo, M. L., *et al.* (2023) Neopeltolide and its synthetic derivatives: a promising new class of anticancer agents. *Front. Pharmacol.* **14**, 1206334
157. Penjweini, R., Roarke, B., Alspaugh, G., Gevorgyan, A., Andreoni, A., Pasut, A., *et al.* (2020) Single cell-based fluorescence lifetime imaging of intracellular oxygenation and metabolism. *Redox Biol.* **34**, 101549
158. Preston, G., El Soufi El Sabbagh, D., Emmerzaal, T. L., Morava, E., Andrezza, A. C., Rahman, S., *et al.* (2023) Antidepressants, mood-stabilizing drugs, and mitochondrial functions: for better or for worse. In: de Oliveira, M. R., ed. *Mitochondrial Intoxication*, Academic Press, Cambridge, MA: 323–349
159. Prochaska, L. J., and Cvetkov, T. L. (2013) Mitochondrial electron transport. In: Roberts, G. C. K., ed. *Encyclopedia of Biophysics*, Springer, Berlin, Heidelberg
160. Protasoni, M., and Zeviani, M. (2021) Mitochondrial structure and bioenergetics in normal and disease conditions. *Int. J. Mol. Sci.* **22**, 586
161. Rahman, S., and Mayr, J. A. (2022) Disorders of oxidative phosphorylation. In: Saudubray, J. M., Baumgartner, M. R., García-Cazorla, Á., Walter, J., eds. *Inborn Metabolic Diseases*, Springer, Berlin, Heidelberg
162. Read, A. D., Bentley, R. E., Archer, S. L., and Dunham-Snary, K. J. (2021) Mitochondrial iron-sulfur clusters: structure, function, and an emerging role in vascular biology. *Redox Biol.* **47**, 102164
163. Risiglione, P., Leggio, L., Cubisino, S. A. M., Reina, S., Paternò, G., Marchetti, B., *et al.* (2020) High-resolution respirometry reveals MPP⁺ mitochondrial toxicity mechanism in a cellular model of Parkinson's disease. *Int. J. Mol. Sci.* **21**, E7809
164. Rodick, T. C., Seibels, D. R., Babu, J. R., Huggins, K. W., Ren, G., and Mathews, S. T. (2018) Potential role of coenzyme Q₁₀ in health and disease conditions. *Nutr. Dietary Supplements* **10**, 1–11
165. Sarmah, D., Kaur, H., Saraf, J., Vats, K., Pravalika, K., Wanve, M., *et al.* (2019) Mitochondrial dysfunction in stroke: implications of stem cell therapy. *Transl. Stroke Res.* <https://doi.org/10.1007/s12975-018-0642-y>
166. Sharma, C., Kim, S., Nam, Y., Jung, U. J., and Kim, S. R. (2021) Mitochondrial dysfunction as a driver of cognitive impairment in Alzheimer's disease. *Int. J. Mol. Sci.* **22**, 4850
167. Shu, P., Liang, H., Zhang, J., Lin, Y., Chen, W., and Zhang, D. (2023) Reactive oxygen species formation and its effect on CD4⁺ T cell-mediated inflammation. *Front. Immunol.* **14**, 1199233
168. Simon, L., and Molina, P. E. (2022) Cellular bioenergetics: experimental evidence for alcohol-induced adaptations. *Function (Oxf.)* **3**, zqac039
169. Smith, J. A. B., Murach, K. A., Dyar, K. A., and Zierath, J. R. (2023) Exercise metabolism and adaptation in skeletal muscle. *Nat. Rev. Mol. Cell Biol.* **24**, 607–632
170. Sommer, N., Alebrahimdehkordi, N., Pak, O., Knoepp, F., Strielkov, I., Scheibe, S., *et al.* (2020) Bypassing mitochondrial Complex III using alternative oxidase inhibits acute pulmonary oxygen sensing. *Sci. Adv.* **6**, eaba0694
171. Spinelli, J. B., and Haigis, M. C. (2018) The multifaceted contributions of mitochondria to cellular metabolism. *Nat. Cell Biol.* **20**, 745–754
172. Srivastava, S. (2016) Emerging therapeutic roles for NAD⁺ metabolism in mitochondrial and age-related disorders. *Clin. Transl. Med.* **5**, 25
173. Szabo, L., Eckert, A., and Grimm, A. (2020) Insights into disease-associated tau impact on mitochondria. *Int. J. Mol. Sci.* **21**, 6344
174. Tang, X., Luo, Y. X., Chen, H. Z., and Liu, D. P. (2014) Mitochondria, endothelial cell function, and vascular diseases. *Front. Physiol.* **5**, 175
175. Thomas, L. W., and Ashcroft, M. (2019) Exploring the molecular interface between hypoxia-inducible factor signalling and mitochondria. *Cell Mol. Life Sci.* **76**, 1759–1777
176. Tian, R., Yin, D., Liu, Y., Seim, I., Xu, S., and Yang, G. (2017) Adaptive evolution of energy metabolism-related genes in hypoxia-tolerant mammals. *Front. Genet.* **8**, 205
177. Tirichen, H., Yaigoub, H., Xu, W., Wu, C., Li, R., and Li, Y. (2021) Mitochondrial reactive oxygen species and their contribution in chronic kidney disease progression through oxidative stress. *Front. Physiol.* **12**, 627837
178. Turtton, N., Cufflin, N., Dewsbury, M., Fitzpatrick, O., Islam, R., Watler, L. L., *et al.* (2022) The biochemical assessment of mitochondrial respiratory chain disorders. *Int. J. Mol. Sci.* **23**, 7487
179. Vayalil, P. K. (2019) Mitochondrial oncobiogenetics of prostate tumorigenesis. *Oncol. Lett.* **18**, 4367–4376
180. Vekshin, N. (2020) *Biophysics of Mitochondria*. Springer, Cham: 197
181. Wang, G., Feng, H., Gao, A., Hao, Q., Jin, W., Peng, X., *et al.* (2016) Extracellular electron transfer from aerobic bacteria to Au-loaded TiO₂ semiconductor without light: a new bacteria-killing mechanism other than localized surface plasmon resonance or microbial fuel cells. *ACS Appl. Mater. Inter.* **8**, 24509–24516
182. Wipf, P., Polyzos, A. A., and McMurray, C. T. (2022) A double-pronged sword: XJB-5-131 is a suppressor of somatic instability and toxicity in Huntington's disease. *J. Huntingtons Dis.* **11**, 3–15
183. Xia, H., Huang, Z., Wang, Z., Liu, S., Zhao, X., You, J., *et al.* (2022) Glucometabolic reprogramming: from trigger to therapeutic target in hepatocellular carcinoma. *Front. Oncol.* **12**, 953668
184. Yang, J., Guo, Q., Feng, X., Liu, Y., and Zhou, Y. (2022) Mitochondrial dysfunction in cardiovascular diseases: potential targets for treatment. *Front. Cell Dev. Biol.* **10**, 841523
185. Yépez, V. A., Kremer, L. S., Iuso, A., Gusic, M., Kopajtich, R., Koňářková, E., *et al.* (2018) OCR-Stats: Robust estimation and statistical testing of mitochondrial respiration activities using Seahorse XF Analyzer. *PLoS One* **13**, e0199938
186. Yuan, Q., Zeng, Z. L., Yang, S., Li, A., Zu, X., and Liu, J. (2022) Mitochondrial stress in metabolic inflammation: modest benefits and full losses. *Oxid. Med. Cell Longev.* **2022**, 8803404
187. Zhang, H., Feng, Y. W., and Yao, Y. M. (2018) Potential therapy strategy: targeting mitochondrial dysfunction in sepsis. *Mil. Med. Res.* **5**, 41
188. Alegre, M. L. (2019) Treg respiration. *Am. J. Transpl.* **19**, 969
189. Ali, E. S., and Ben-Sahra, I. (2023) Regulation of nucleotide metabolism in cancers and immune disorders. *Trends Cell Biol.* **33**, 950–966
190. Balaban, R. S., Nemoto, S., and Finkel, T. (2005) Mitochondria, oxidants, and aging. *Cell* **120**, 483–495
191. Bansal, A., Rashid, C., and Simmons, R. A. (2019) Impact of fetal programming on mitochondrial function and susceptibility to obesity and type 2 diabetes. In: Morio, B., Pénicaud, L., Rigoulet, M., eds. *Mitochondria in Obesity and Type 2 Diabetes*, Academic Press, Cambridge, MA
192. Bertero, E., and Maack, C. (2018) Metabolic remodelling in heart failure. *Nat. Rev. Cardiol.* **15**, 457–470

193. Bertero, E., and Maack, C. (2022) Rethinking Mitchell's chemiosmotic theory: potassium dominates over proton flux to drive mitochondrial F_1F_0 -ATP synthase. *Function (Oxf)* **3**, zqac012
194. Chang, J. S. (2023) Recent insights into the molecular mechanisms of simultaneous fatty acid oxidation and synthesis in brown adipocytes. *Front. Endocrinol. (Lausanne)* **14**, 1106544
195. Chen, C. L., Zhang, L., Jin, Z., Kasumov, T., and Chen, Y. R. (2022) Mitochondrial redox regulation and myocardial ischemia-reperfusion injury. *Am. J. Physiol. Cell Physiol.* **322**, C12–C23
196. Chen, Y. R., and Zweier, J. L. (2014) Cardiac mitochondria and reactive oxygen species generation. *Circ. Res.* **114**, 524–537
197. Chowdhury, R. S., and Banerji, V. (2018) Targeting mitochondrial bioenergetics as a therapeutic strategy for chronic lymphocytic leukemia. *Oxid. Med. Cell Longev.* **2018**, 2426712
198. Connolly, N. M. C., Theurey, P., Adam-Vizi, V., Bazan, N. G., Bernardi, P., Bolaños, J. P., et al. (2018) Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases. *Cell Death Differ.* **25**, 542–572
199. Cortez-Pinto, H., and Machado, M. V. (2009) Uncoupling proteins and non-alcoholic fatty liver disease. *J. Hepatol.* **50**, 857–860
200. Dawson, J. (2021) *Oxidative Phosphorylation: The Electron Transport Chain, Chapter 23*. Open Library, Pressbooks, Montreal, QC
201. DiMauro, S., and Schon, E. A. (2003) Mitochondrial respiratory-chain diseases. *N. Engl. J. Med.* **348**, 2656–2668
202. Fogg, V. C., Lanning, N. J., and MacKeigan, J. P. (2011) Mitochondria in cancer: at the crossroads of life and death. *Chin J. Cancer* **30**, 526–539
203. Forbes, J. M., and Thorburn, D. R. (2018) Mitochondrial dysfunction in diabetic kidney disease. *Nat. Rev. Nephrol.* **14**, 291–312
204. Frangos, S. M., DesOrmeaux, G. J., and Holloway, G. P. (2023) Acidosis attenuates CPT-I supported bioenergetics as a potential mechanism limiting lipid oxidation. *J. Biol. Chem.* **299**, 105079
205. Gao, Y. M., Feng, S. T., Wen, Y., Tang, T. T., Wang, B., and Liu, B. C. (2022) Cardiorenal protection of SGLT2 inhibitors-Perspectives from metabolic reprogramming. *Ebiomedicine* **83**, 104215
206. Gatti, P., Ilamathi, H. S., Todkar, K., and Germain, M. (2020) Mitochondria targeted viral replication and survival strategies-prospective on SARS-CoV-2. *Front. Pharmacol.* **11**, 578599
207. Granger, D. N., and Kvietys, P. R. (2015) Reperfusion injury and reactive oxygen species: the evolution of a concept. *Redox Biol.* **6**, 524–551
208. Himms-Hagen, J., and Harper, M. E. (2001) Physiological role of UCP3 may be export of fatty acids from mitochondria when fatty acid oxidation predominates: an hypothesis. *Exp. Biol. Med. (Maywood)*. **226**, 78–84
209. Ishii, I., Harada, Y., and Kasahara, T. (2012) Reprofile a classical anthelmintic, pyriminium pamoate, as an anti-cancer drug targeting mitochondrial respiration. *Front. Oncol.* **2**, 137
210. Jia, D., Park, J. H., Jung, K. H., Levine, H., and Kaiparettu, B. A. (2018) Elucidating the metabolic plasticity of cancer: mitochondrial reprogramming and hybrid metabolic states. *Cells* **7**, 21
211. Jochmanova, I., and Pacak, K. (2016) Pheochromocytoma: the first metabolic endocrine cancer. *Clin. Cancer Res.* **22**, 5001–5011
212. Klimova, T., and Chandel, N. S. (2008) Mitochondrial Complex III regulates hypoxic activation of HIF. *Cell Death Differ.* **15**, 660–666
213. Lewis, M. T., Kasper, J. D., Bazil, J. N., Frisbee, J. C., and Wiseman, R. W. (2019) Quantification of mitochondrial oxidative phosphorylation in metabolic disease: application to Type 2 diabetes. *Int. J. Mol. Sci.* **20**, 5271
214. Liu, Y., and Schubert, D. R. (2009) The specificity of neuroprotection by antioxidants. *J. Biomed. Sci.* **16**, 98
215. Ma, Y., Temkin, S. M., Hawkrige, A. M., Guo, C., Wang, W., Wang, X. Y., et al. (2018) Fatty acid oxidation: an emerging facet of metabolic transformation in cancer. *Cancer Lett.* **435**, 92–100
216. Ma, Y., Wang, W., Devarakonda, T., Zhou, H., Wang, X. Y., Salloum, F. N., et al. (2020) Functional analysis of molecular and pharmacological modulators of mitochondrial fatty acid oxidation. *Sci. Rep.* **10**, 1450
217. Merlin, J., Ivanov, S., Dumont, A., Sergushichev, A., Gall, J., Stunault, M., et al. (2021) Non-canonical glutamine transamination sustains efferocytosis by coupling redox buffering to oxidative phosphorylation. *Nat. Metab.* **3**, 1313–1326
218. Merritt, J. L., 2nd, MacLeod, E., Jurecka, A., and Hainline, B. (2020) Clinical manifestations and management of fatty acid oxidation disorders. *Rev. Endocr. Metab. Disord.* **21**, 479–493
219. Müller, M., Donhauser, E., Maske, T., Bischof, C., Dumitrescu, D., Rudolph, V., et al. (2023) Mitochondrial integrity is critical in right heart failure development. *Int. J. Mol. Sci.* **24**, 11108
220. Murray, A. J. (2009) Metabolic adaptation of skeletal muscle to high altitude hypoxia: how new technologies could resolve the controversies. *Genome Med.* **1**, 117
221. Nussbaum, R. L. (2005) Mining yeast *in silico* unearths a golden nugget for mitochondrial biology. *J. Clin. Invest.* **115**, 2689–2691
222. Pacifico, F., Leonardi, A., and Crescenzi, E. (2023) Glutamine metabolism in cancer stem cells: a complex liaison in the tumor microenvironment. *Int. J. Mol. Sci.* **24**, 2337
223. Pendleton, K. E., Wang, K., and Echeverria, G. V. (2023) Rewiring of mitochondrial metabolism in therapy-resistant cancers: permanent and plastic adaptations. *Front. Cell Dev. Biol.* **11**, 1254313
224. Pharaoh, G., Kamat, V., Kannan, S., Stuppard, R. S., Whitson, J., Martín-Pérez, M., et al. (2023) The mitochondrially targeted peptide elamipretide (SS-31) improves ADP sensitivity in aged mitochondria by increasing uptake through the adenine nucleotide translocator (ANT). *Geroscience*. <https://doi.org/10.1007/s11357-023-00861-y>
225. Picard, M., Jung, B., Liang, F., Azuelos, I., Hussain, S., Goldberg, P., et al. (2012) Mitochondrial dysfunction and lipid accumulation in the human diaphragm during mechanical ventilation. *Am. J. Respir. Crit. Care Med.* **186**, 1140–1149
226. Polyzos, A. A., and McMurray, C. T. (2017) The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington's disease. *Mech. Ageing Dev.* **161**, 181–197
227. Prasun, P. (2020) Role of mitochondria in pathogenesis of type 2 diabetes mellitus. *J. Diabetes Metab. Disord.* **19**, 2017–2022
228. Radogna, F., Gerard, D., Dicato, M., and Diederich, M. (2021) Assessment of Mmitochondrial cell metabolism by respiratory chain electron flow assays. *Methods Mol. Biol.* **2276**, 129–141
229. Raimondi, V., Ciccamese, F., and Ciminale, V. (2020) Oncogenic pathways and the electron transport chain: a dangerROS liaison. *Br. J. Cancer* **122**, 168–181
230. Rose, S., and Bennuri, S. C. (2019) Mitochondrial metabolism. In: Frye, R., Berk, M., eds. *The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine*, Adis, Singapore
231. Sadri, S., Zhang, X., Audi, S. H., Cowley, A. W., Jr., and Dash, R. K. (2023) Computational modeling of substrate-dependent mitochondrial respiration and bioenergetics in the heart and kidney cortex and outer medulla. *Function (Oxf)*. **4**, zqad038
232. Shadel, G. S. (2005) Mitochondrial DNA, aconitase 'wraps' it up. *Trends Biochem. Sci.* **30**, 294–296
233. Sivitz, W. I. (2017) Techniques to investigate bioenergetics of mitochondria. In: Strack, S., Usachev, Y., eds., *Techniques to Investigate Mitochondrial Function in Neurons. Neuromethods* **123** pp. 67–94
234. Snyder, C. M., and Chandel, N. S. (2009) Mitochondrial regulation of cell survival and death during low-oxygen conditions. *Antioxid. Redox Signal.* **11**, 2673–2683
235. Speijer, D. (2016) Being right on Q: shaping eukaryotic evolution. *Biochem. J.* **473**, 4103–4127
236. Vockley, J. (2021) Inborn errors of fatty acid oxidation. In: *Liver Disease in Children*, Cambridge University Press, Cambridge, UK: 611–627
237. Vorotnikov, A. V., Khapchayev, A. Y., Nickashin, A. V., and Shirinsky, V. P. (2022) *In vitro* modeling of diabetes impact on vascular endothelium: are essentials engaged to tune metabolism? *Biomedicines* **10**, 3181
238. Yang, Y., Wu, Y., Sun, X. D., and Zhang, Y. (2021) Reactive oxygen species, glucose metabolism, and lipid metabolism. In: Huang, C., Zhang, Y., eds. *Oxidative Stress*, Springer, Singapore
239. Zhang, X., Tomar, N., Kandel, S. M., Audi, S. H., Cowley, A. W., Jr., and Dash, R. K. (2021) Substrate- and calcium-dependent differential regulation of mitochondrial oxidative phosphorylation and energy production in the heart and kidney. *Cells* **11**, 131

240. Zhao, H., and Li, Y. (2021) Cancer metabolism and intervention therapy. *Mol. Biomed.* **2**, 5
241. Cowan, K., Anichtchik, O., and Luo, S. (2019) Mitochondrial integrity in neurodegeneration. *CNS Neurosci. Ther.* **25**, 825–836
242. Ahmad, M., Wolberg, A., and Kahwaji, C. I. (2022) *Biochemistry, Electron Transport Chain*, StatPearls Publishing, Treasure Island (FL)
243. Alston, C. L., Rocha, M. C., Lax, N. Z., Turnbull, D. M., and Taylor, R. W. (2017) The genetics and pathology of mitochondrial disease. *J. Pathol.* **241**, 236–250
244. Anoar, S., Woodling, N. S., and Niccoli, T. (2021) Mitochondria dysfunction in frontotemporal dementia/amyotrophic lateral sclerosis: lessons from *Drosophila* models. *Front. Neurosci.* **15**, 786076
245. Chen, T. H., Koh, K. Y., Lin, K. M., and Chou, C. K. (2022) Mitochondrial dysfunction as an underlying cause of skeletal muscle disorders. *Int. J. Mol. Sci.* **23**, 12926
246. Cojocaru, K. A., Luchian, I., Goriuc, A., Antoci, L. M., Ciobanu, C. G., Popescu, R., et al. (2023) Mitochondrial dysfunction, oxidative stress, and therapeutic strategies in diabetes, obesity, and cardiovascular disease. *Antioxidants (Basel)*. **12**, 658
247. Dilliraj, L. N., Schiuma, G., Lara, D., Strazzabosco, G., Clement, J., Giovannini, P., et al. (2022) The evolution of ketosis: potential impact on clinical conditions. *Nutrients* **14**, 3613
248. Distelmaier, F., Koopman, W. J., van den Heuvel, L. P., Rodenburg, R. J., Mayatepek, E., Willems, P. H., et al. (2009) Mitochondrial Complex I deficiency: from organelle dysfunction to clinical disease. *Brain* **132**, 833–842
249. Egan, B., and Sharples, A. P. (2023) Molecular responses to acute exercise and their relevance for adaptations in skeletal muscle to exercise training. *Physiol. Rev.* **103**, 2057–2170
250. El-Gammal, Z., Nasr, M. A., Elmehra, A. O., Salah, R. A., Saad, S. M., and El-Badri, N. (2022) Regulation of mitochondrial temperature in health and disease. *Pflugers Arch.* **474**, 1043–1051
251. Fahimi, P., and Matta, C. F. (2022) The hot mitochondrion paradox: reconciling theory and experiment. *Trends Chem.* **4**, 4–20
252. Faria, R., Boisuéirin, P., Sousa, Á., and Costa, D. (2023) Delivery systems for mitochondrial gene therapy: a review. *Pharmaceutics* **15**, 572
253. Foo, J., Bellot, G., Pervaiz, S., and Alonso, S. (2022) Mitochondria-mediated oxidative stress during viral infection. *Trends Microbiol.* **30**, 679–692
254. George, C. E., Saunders, C. V., Morrison, A., Scorer, T., Jones, S., and Dempsey, N. C. (2023) Cold stored platelets in the management of bleeding: is it about bioenergetics? *Platelets* **34**, 2188969
255. Gopalakrishnan, S., Mehrvar, S., Maleki, S., Schmitt, H., Summerfelt, P., Dubis, A. M., et al. (2020) Photobiomodulation preserves mitochondrial redox state and is retinoprotective in a rodent model of retinitis pigmentosa. *Sci. Rep.* **10**, 20382
256. Hidalgo-Gutiérrez, A., González-García, P., Díaz-Casado, M. E., Barriocanal-Casado, E., López-Herrador, S., Quinzii, C. M., et al. (2021) Metabolic targets of coenzyme Q₁₀ in mitochondria. *Antioxidants (Basel)* **10**, 520
257. Ignatieva, E., Smolina, N., Kostareva, A., and Dmitrieva, R. (2021) Skeletal muscle mitochondria dysfunction in genetic neuromuscular disorders with cardiac phenotype. *Int. J. Mol. Sci.* **22**, 7349
258. Joshi, A., Ito, T., Picard, D., and Neckers, L. (2022) The mitochondrial HSP90 paralogue TRAP1: structural dynamics, interactome, role in metabolic regulation, and inhibitors. *Biomolecules* **12**, 880
259. Kalainayakan, S. P., FitzGerald, K. E., Konduri, P. C., Vidal, C., and Zhang, L. (2018) Essential roles of mitochondrial and heme function in lung cancer bioenergetics and tumorigenesis. *Cell Biosci.* **8**, 56
260. Koene, S., Willems, P. H., Roestenberg, P., Koopman, W. J., and Smeitink, J. A. (2011) Mouse models for nuclear DNA-encoded mitochondrial complex I deficiency. *J. Inher. Metab. Dis.* **34**, 293–307
261. Lee, W. E., Genetzakis, E., and Figtree, G. A. (2023) Novel strategies in the early detection and treatment of endothelial cell-specific mitochondrial dysfunction in coronary artery disease. *Antioxidants (Basel)* **12**, 1359
262. Lu, F. (2023) Hypothetical hydrogenase activity of human mitochondrial Complex I and its role in preventing cancer transformation. *Explor Res. Hypothesis Med.* **8**, 280–285
263. Manickam, D. S. (2022) Delivery of mitochondria via extracellular vesicles - a new horizon in drug delivery. *J. Control Release* **343**, 400–407
264. Martell, E., Kuzmychova, H., Kaul, E., Senthil, H., Chowdhury, S. R., Morrison, L. C., et al. (2023) Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. *Nat. Commun.* **14**, 2502
265. Mejia-Vergara, A. J., Seleme, N., Sadun, A. A., and ND Karanjia, R. (2020) Pathophysiology of conversion to symptomatic leber hereditary optic neuropathy and therapeutic implications: a review. *Curr. Neurol. Neurosci. Rep.* **20**, 11
266. Musicco, C., Signorile, A., Pesce, V., Loguercio Polosa, P., and Cormio, A. (2023) Mitochondria deregulations in cancer offer several potential targets of therapeutic interventions. *Int. J. Mol. Sci.* **24**, 10420
267. Nguyen, T. T., Nguyen, D. K., and Ou, Y. Y. (2021) Addressing data imbalance problems in ligand-binding site prediction using a variational autoencoder and a convolutional neural network. *Brief Bioinform* **22**, bbab277
268. Payen, V. L., Zampieri, L. X., Porporato, P. E., and Sonveaux, P. (2019) Pro- and antitumor effects of mitochondrial reactive oxygen species. *Cancer Metast. Rev.* **38**, 189–203
269. Prasuhn, J., Davis, R. L., and Kumar, K. R. (2021) Targeting mitochondrial impairment in Parkinson's disease: challenges and opportunities. *Front. Cell Dev. Biol.* **8**, 615461
270. Sainero-Alcolado, L., Liaño-Pons, J., Ruiz-Pérez, M. V., and Arsenian-Henriksson, M. (2022) Targeting mitochondrial metabolism for precision medicine in cancer. *Cell Death Differ.* **29**, 1304–1317
271. Schniertshauer, D., Wespel, S., and Bergemann, J. (2023) Natural mitochondria targeting substances and their effect on cellular antioxidant system as a potential benefit in mitochondrial medicine for prevention and remediation of mitochondrial dysfunctions. *Curr. Issues Mol. Biol.* **45**, 3911–3932
272. Shields, H. J., Traa, A., and Van Raamsdonk, J. M. (2021) Beneficial and detrimental effects of reactive oxygen species on lifespan: a comprehensive review of comparative and experimental studies. *Front. Cell Dev. Biol.* **9**, 628157
273. Solhaug, A., Gjessing, M., Sandvik, M., and Eriksen, G. S. (2023) The gill epithelial cell lines RTgill-W1, from rainbow trout and ASG-10, from atlantic salmon, exert different toxicity profiles towards rotenone. *Cytotechnology* **75**, 63–75
274. Tseng, W.-W., and Wei, A.-C. (2022) Kinetic mathematical modeling of oxidative phosphorylation in cardiomyocyte mitochondria. *Cells* **11**, 4020
275. Turton, N., Bowers, N., Khajeh, S., Hargreaves, I. P., and Heaton, R. A. (2021) Coenzyme Q₁₀ and the exclusive club of diseases that show a limited response to treatment. *Expert Opin. Orphan Drugs* **9**, 151–160
276. Vargas-Mendoza, N., Angeles-Valencia, M., Morales-González, Á., Madrigal-Santillán, E. O., Morales-Martínez, M., Madrigal-Bujaidar, E., et al. (2021) Oxidative stress, mitochondrial function and adaptation to exercise: new perspectives in nutrition. *Life (Basel)* **11**, 1269
277. Vesga, L. C., Silva, A. M. P., Bernal, C. C., Mendez-Sánchez, S. C., and Bohórquez, A. R. R. (2021) Tetrahydroquinoline/4,5-dihydroisoxazole hybrids with a remarkable effect over mitochondrial bioenergetic metabolism on melanoma cell line B16F10. *Med. Chem. Res.* **30**, 2127–2143
278. Wu, Z., Ho, W. S., and Lu, R. (2022) Targeting mitochondrial oxidative phosphorylation in glioblastoma therapy. *Neuromol. Med.* **24**, 18–22
279. Yang, Y., Zhang, X., Hu, X., Zhao, J., Chen, X., Wei, X., et al. (2022) Analysis of the differential metabolic pathway of cultured *Chlorococcum humicola* with hydroquinone toxic sludge extract. *J. Clean. Prod.* **370**, 133486
280. Yin, M., and O'Neill, L. A. J. (2021) The role of the electron transport chain in immunity. *FASEB J.* **35**, e21974

281. Area-Gomez, E., Guardia-Laguarta, C., Schon, E. A., and Przedborski, S. (2019) Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas. *J. Clin. Invest.* **129**, 34–45
282. Bennett, C. F., Latorre-Muro, P., and Puigserver, P. (2022) Mechanisms of mitochondrial respiratory adaptation. *Nat. Rev. Mol. Cell Biol.* **23**, 817–835
283. Bennett, M. J., Sheng, F., and Saada, A. (2020) Biochemical assays of TCA cycle and β -oxidation metabolites. *Methods Cell Biol.* **155**, 83–120
284. Carriere, A., and Casteilla, L. (2019) Role of mitochondria in adipose tissues metabolism and plasticity. In: Morio, B., Pénicaud, L., Rigoutet, M., eds. *Mitochondria in Obesity and Type 2 Diabetes*, Academic Press, Cambridge, MA
285. Che, X., Zhang, T., Li, H., Li, Y., Zhang, L., and Liu, J. (2023) Nighttime hypoxia effects on ATP availability for photosynthesis in seagrass. *Plant Cell Environ* **46**, 2841–2850
286. Chi, S. C., Cheng, H. C., and Wang, A. G. (2022) Leber hereditary optic neuropathy: molecular pathophysiology and updates on gene therapy. *Biomedicines* **10**, 1930
287. Duan, J., Chen, Z., Wu, Y., Zhu, B., Yang, L., and Yang, C. (2019) Metabolic remodeling induced by mitokines in heart failure. *Aging (Albany NY)* **11**, 7307–7327
288. Fisher-Wellman, K. H., and Neuffer, P. D. (2012) Linking mitochondrial bioenergetics to insulin resistance via redox biology. *Trends Endocrinol. Metab.* **23**, 142–153
289. Flones, I. H., and Tzoulis, C. (2022) Mitochondrial respiratory chain dysfunction—a hallmark pathology of idiopathic Parkinson’s disease? *Front. Cell Dev. Biol.* **10**, 874596
290. Gero, D. (2017) *Hyperglycemia-Induced Endothelial Dysfunction*. IntechOpen, London, UK
291. Kikusato, M., Furukawa, K., Kamizono, T., Hakamata, Y., and Toyomizu, M. (2016) Roles of mitochondrial oxidative phosphorylation and reactive oxygen species generation in the metabolic modification of avian skeletal muscle. *Proc. Jpn. Soc. Anim. Nutr. Metab.* **60**, 57–68
292. Knott, A. B., and Bossy-Wetzel, E. (2009) Nitric oxide in health and disease of the nervous system. *Antioxid. Redox Signal.* **11**, 541–554
293. Kraegen, E. W., Cooney, G. J., and Turner, N. (2008) Muscle insulin resistance: a case of fat overconsumption, not mitochondrial dysfunction. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 7627–7628
294. Lettieri-Barbato, D. (2019) Redox control of non-shivering thermogenesis. *Mol. Metab.* **25**, 11–19
295. Loussouarn, C., Pers, Y. M., Bony, C., Jorgensen, C., and Noël, D. (2021) Mesenchymal stromal cell-derived extracellular vesicles regulate the mitochondrial metabolism via transfer of miRNAs. *Front. Immunol.* **12**, 623973
296. Mracek, T., Drahotka, Z., and Houstek, J. (2013) The function and the role of the mitochondrial glycerol-3-phosphate dehydrogenase in mammalian tissues. *Biochim. Biophys. Acta* **1827**, 401–410
297. Onukwufor, J. O., Dirksen, R. T., and Wojtovich, A. P. (2022) Iron dysregulation in mitochondrial dysfunction and Alzheimer’s disease. *Antioxidants (Basel)*. **11**, 692
298. Perouansky, M., Johnson-Schlitz, D., Sedensky, M. M., and Morgan, P. G. (2023) A primordial target: mitochondria mediate both primary and collateral anesthetic effects of volatile anesthetics. *Exp. Biol. Med. (Maywood)*. **248**, 545–552
299. Rinaldo, P., Matern, D., and Bennett, M. J. (2002) Fatty acid oxidation disorders. *Annu. Rev. Physiol.* **64**, 477–502
300. Sacchetto, C., Sequeira, V., Bertero, E., Dudek, J., Maack, C., and Calore, M. (2019) Metabolic alterations in inherited cardiomyopathies. *J. Clin. Med.* **8**, 2195
301. Schinagl, C. W., Vrabl, P., and Burgstaller, W. (2016) Adapting high-resolution respirometry to glucose-limited steady state mycelium of the filamentous fungus *Penicillium ochrochloron*: method development and standardisation. *PLoS One* **11**, e0146878
302. Schottlender, N., Gottfried, I., and Ashery, U. (2021) Hyperbaric oxygen treatment: effects on mitochondrial function and oxidative stress. *Biomolecules* **11**, 1827
303. Shirakawa, R., Nakajima, T., Yoshimura, A., Kawahara, Y., Orito, C., Yamane, M., et al. (2023) Enhanced mitochondrial oxidative metabolism in peripheral blood mononuclear cells is associated with fatty liver in obese young adults. *Sci. Rep.* **13**, 52032
304. Sullivan, L. B., and Chandel, N. S. (2014) Mitochondrial metabolism in TCA cycle mutant cancer cells. *Cell Cycle* **13**, 347–348
305. Tanaka, M., Szabó, Á., Spekker, E., Polyák, H., Tóth, F., and Vécsei, L. (2022) Mitochondrial impairment: a common motif in neuropsychiatric presentation? The link to the tryptophan-kynurenine metabolic system. *Cells* **11**, 2607
306. Valle-Mendiola, A., and Soto-Cruz, I. (2020) Energy metabolism in cancer: the roles of STAT3 and STAT5 in the regulation of metabolism-related genes. *Cancers (Basel)* **12**, 124
307. Vartak, R., Porras, C. A., and Bai, Y. (2013) Respiratory supercomplexes: structure, function and assembly. *Protein Cell* **4**, 582–590
308. Wang, K., Jiang, J., Lei, Y., Zhou, S., Wei, Y., and Huang, C. (2019) Targeting metabolic-redox circuits for cancer therapy. *Trends Biochem. Sci.* **44**, 401–414
309. Wang, R., Liang, L., Matsumoto, M., Iwata, K., Umemura, A., and He, F. (2023) Reactive oxygen species and NRF2 signaling, friends or foes in cancer? *Biomolecules* **13**, 353
310. Zhao, H., Swanson, K. D., and Zheng, B. (2021) Therapeutic repurposing of biguanides in cancer. *Trends Cancer* **7**, 714–730
311. Lima, A., Lubatti, G., Burgstaller, J., Hu, D., Green, A. P., Di Gregorio, A., et al. (2021) Cell competition acts as a purifying selection to eliminate cells with mitochondrial defects during early mouse development. *Nat. Metab.* **3**, 1091–1108
312. Liu, R., Jagannathan, R., Sun, L., Li, F., Yang, P., Lee, J., et al. (2020) Tead1 is essential for mitochondrial function in cardiomyocytes. *Am. J. Physiol. Heart Circ. Physiol.* **319**, H89–H99
313. Bratic, A., and Larsson, N. G. (2013) The role of mitochondria in aging. *J. Clin. Invest.* **123**, 951–957
314. Brischigliaro, M., and Zeviani, M. (2021) Cytochrome *c* oxidase deficiency. *Biochim. Biophys. Acta Bioenerg.* **1862**, 148335
315. Cerqua, C., Buson, L., and Trevisson, E. (2021) Mutations in assembly factors required for the biogenesis of mitochondrial respiratory chain. In: Navas, P., Salviati, L., eds. *Mitochondrial Diseases*, Springer, Cham
316. DeBalsi, K. L., Hoff, K. E., and Copeland, W. C. (2017) Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases. *Ageing Res. Rev.* **33**, 89–104
317. Gallinat, A., Vilahur, G., Padró, T., and Badimon, L. (2022) Network-assisted systems biology analysis of the mitochondrial proteome in a pre-clinical model of ischemia, revascularization and post-conditioning. *Int. J. Mol. Sci.* **23**, 2087
318. Głombik, K., Detka, J., and Budziszewska, B. (2021) Hormonal regulation of oxidative phosphorylation in the brain in health and disease. *Cells* **10**, 2937
319. Keidar, N., Peretz, N. K., and Yaniv, Y. (2023) Ca^{2+} pushes and pulls energetics to maintain ATP balance in atrial cells: computational insights. *Front. Physiol.* **14**, 1231259
320. Yan, L. J. (2014) Pathogenesis of chronic hyperglycemia: from reductive stress to oxidative stress. *J. Diabetes Res.* **2014**, 137919
321. Cadonic, C., Sabbir, M. G., and Albensi, B. C. (2016) Mechanisms of mitochondrial dysfunction in Alzheimer’s disease. *Mol. Neurobiol.* **53**, 6078–6090
322. Kezic, A., Spasojevic, I., Lezaic, V., and Bajcetic, M. (2016) Mitochondria-targeted antioxidants: future perspectives in kidney ischemia reperfusion injury. *Oxid. Med. Cell Longev.* **2016**, 2950503
323. Li, X., Fang, P., Mai, J., Choi, E. T., Wang, H., and Yang, X. F. (2013) Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. *J. Hematol. Oncol.* **6**, 19
324. Liskova, A., Samec, M., Koklesova, L., Kudela, E., Kubatka, P., and Golubnitschaja, O. (2021) Mitochondriopathies as a clue to systemic disorders—analytical tools and mitigating measures in context of predictive, preventive, and personalized (3P) medicine. *Int. J. Mol. Sci.* **22**, 2007
325. Sander, W. J., Fourie, C., Sabiu, S., O’Neill, F. H., Pohl, C. H., and O’Neill, H. G. (2022) Reactive oxygen species as potential antiviral targets. *Rev. Med. Virol.* **32**, e2240

326. Steiner, J. L., and Lang, C. H. (2017) Etiology of alcoholic cardiomyopathy: mitochondria, oxidative stress and apoptosis. *Int. J. Biochem. Cell Biol.* **89**, 125–135
327. Tabassum, N., Kheya, I. S., Ibn Asaduzzaman, S. A., Maniha, S. M., Fayz, A. H., Zakaria, A., *et al.* (2020) A review on the possible leakage of electrons through the electron transport chain within mitochondria. *J. Biomed. Res. Environ. Sci.* **1**, 105–113
328. Yang, L., Youngblood, H., Wu, C., and Zhang, Q. (2020) Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation. *Transl. Neurodegener.* **9**, 19
329. Yu, T., Wang, L., Zhang, L., and Deuster, P. A. (2023) Mitochondrial fission as a therapeutic target for metabolic diseases: insights into antioxidant strategies. *Antioxidants (Basel)* **12**, 1163
330. Burgin, H. J., and McKenzie, M. (2020) Understanding the role of OXPHOS dysfunction in the pathogenesis of ECHS1 deficiency. *FEBS Lett.* **594**, 590–610
331. Achreja, A., Yu, T., Mittal, A., Choppara, S., Animasahun, O., Nenwani, M., *et al.* (2022) Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer. *Nat. Metab.* **4**, 1119–1137
332. Torres, M. J., Kew, K. A., Ryan, T. E., Pennington, E. R., Lin, C. T., Buddo, K. A., *et al.* (2018) 17 β -estradiol directly lowers mitochondrial membrane microviscosity and improves bioenergetic function in skeletal muscle. *Cell Metab.* **27**, 167–179
333. Johnson, X., and Alric, J. (2013) Central carbon metabolism and electron transport in *Chlamydomonas reinhardtii*: metabolic constraints for carbon partitioning between oil and starch. *Eukaryot. Cell* **12**, 776–793
334. Kuznetsov, A. V., Margreiter, R., Ausserlechner, M. J., and Hagenbuchner, J. (2022) The complex interplay between mitochondria, ROS and entire cellular metabolism. *Antioxidants (Basel)* **11**, 1995
335. Diaz, E. C., Adams, S. H., Weber, J. L., Cotter, M., and Børsheim, E. (2023) Elevated LDL-C, high blood pressure, and low peak VO₂ associate with platelet mitochondria function in children-The Arkansas Active Kids Study. *Front. Mol. Biosci.* **10**, 1136975
336. Ježek, P., Jabůrek, M., Holendová, B., Engstová, H., and Dlasková, A. (2023) Mitochondrial cristae morphology reflecting metabolism, superoxide formation, redox homeostasis, and pathology. *Antioxid. Redox Signal.* **39**, 635–683
337. Grasso, D., Zampieri, L. X., Capelôa, T., Van de Velde, J. A., and Sonveaux, P. (2020) Mitochondria in cancer. *Cell Stress* **4**, 114–146
338. Middleton, P., and Vergis, N. (2021) Mitochondrial dysfunction and liver disease: role, relevance, and potential for therapeutic modulation. *Therap. Adv. Gastroenterol.* **14**. <https://doi.org/10.1177/17562848211031394>
339. Moudgil, R., Michelakis, E. D., and Archer, S. L. (2005) Hypoxic pulmonary vasoconstriction. *J. Appl. Physiol.* (1985) **98**, 390–403
340. Puntel, R. L., Roos, D. H., Seeger, R. L., and Rocha, J. B. (2013) Mitochondrial electron transfer chain complexes inhibition by different organochalcogens. *Toxicol. In Vitro* **27**, 59–70
341. Xing, Y. (2022) Is genome instability a significant cause of aging? a review. In: *Advances in Social Science, Education and Humanities Research*, **664**. Atlantis Press, Dordrecht, ZH
342. Catania, A., Iuso, A., Bouchereau, J., Kremer, L. S., Paviolo, M., Terrile, C., *et al.* (2019) *Arabidopsis thaliana* alternative dehydrogenases: a potential therapy for mitochondrial complex I deficiency? Perspectives and pitfalls. *Orphanet J. Rare Dis.* **14**, 236
343. Ahmad, G., Almasry, M., Dhillon, A. S., Abuayyash, M. M., Kothandaraman, N., and Cakar, Z. (2017) Overview and sources of reactive oxygen species (ROS) in the reproductive system. In: Agarwal, A., *et al.* eds. *Oxidative Stress in Human Reproduction*, Springer, Cham
344. Irazabal, M. V., and Torres, V. E. (2020) Reactive oxygen species and redox signaling in chronic kidney disease. *Cells* **9**, 1342
345. LaMoia, T. E., Butrico, G. M., Kalpage, H. A., Goedeke, L., Hubbard, B. T., Vatner, D. F., *et al.* (2022) Metformin, phenformin, and galegine inhibit complex IV activity and reduce glycerol-derived gluconeogenesis. *Proc. Natl. Acad. Sci. U. S. A.* **119**, e2122287119
346. Chinopoulos, C. (2013) Which way does the citric acid cycle turn during hypoxia? The critical role of α -ketoglutarate dehydrogenase Complex. *J. Neurosci. Res.* **91**, 1030–1043
347. Andrieux, P., Chevillard, C., Cunha-Neto, E., and Nunes, J. P. S. (2021) Mitochondria as a cellular hub in infection and inflammation. *Int. J. Mol. Sci.* **22**, 11338
348. Huss, J. M., and Kelly, D. P. (2005) Mitochondrial energy metabolism in heart failure: a question of balance. *J. Clin. Invest.* **115**, 547–555
349. Bindra, S., McGill, M. A., Triplett, M. K., Tyagi, A., Thaker, P. H., Dahmouh, L., *et al.* (2021) Mitochondria in epithelial ovarian carcinoma exhibit abnormal phenotypes and blunted associations with bio-behavioral factors. *Sci. Rep.* **11**, 11595
350. Bugariski, M., Martins, J. R., Haenni, D., and Hall, A. M. (2018) Multiphoton imaging reveals axial differences in metabolic autofluorescence signals along the kidney proximal tubule. *Am. J. Physiol. Ren. Physiol.* **315**, F1613–F1625
351. Cortassa, S., Aon, M. A., and Sollott, S. J. (2019) Control and regulation of substrate selection in cytoplasmic and mitochondrial catabolic networks. A systems biology analysis. *Front. Physiol.* **10**, 201
352. Karan, K. R., Trumpff, C., McGill, M. A., Thomas, J. E., Sturm, G., Lauriola, V., *et al.* (2020) Mitochondrial respiratory capacity modulates LPS-induced inflammatory signatures in human blood. *Brain Behav. Immun. Health* **5**, 100080
353. Picard, M., and McEwen, B. S. (2018) Psychological stress and mitochondria: a systematic review. *Psychosom Med.* **80**, 141–153
354. Picard, M., Prather, A. A., Puterman, E., Cuillerier, A., Coccia, M., Aschbacher, K., *et al.* (2018) A mitochondrial health index sensitive to mood and caregiving stress. *Biol. Psych.* **84**, 9–17
355. Rausser, S., Trumpff, C., McGill, M. A., Junker, A., Wang, W., Ho, S. H., *et al.* (2021) Mitochondrial phenotypes in purified human immune cell subtypes and cell mixtures. *Elife* **10**, e70899
356. Gnaiger, E. (2023) Complex II ambiguities — FADH₂ in the electron transfer system: supporting materials. *MitoFit Preprints* **2023**. <https://doi.org/10.26124/mitofit:2023-0003.v6>
357. Houten, S. M., Violante, S., Ventura, F. V., and Wanders, R. J. (2016) The biochemistry and physiology of mitochondrial fatty acid β -oxidation and its genetic disorders. *Annu. Rev. Physiol.* **78**, 23–44
358. Crane, F. L., and Beinert, H. (1954) A link between fatty acyl CoA dehydrogenase and cytochrome c: a new flavin enzyme. *J. Am. Chem. Soc.* **76**, 4491
359. Crane, F. L., and Beinert, H. (1956) On the mechanism of dehydrogenation of fatty acyl derivatives of coenzyme A. II. The electron-transferring flavoprotein. *J. Biol. Chem.* **218**, 717–731
360. Wang, Y., Palmfeldt, J., Gregersen, N., Makhov, A. M., Conway, J. F., Wang, M., *et al.* (2019) Mitochondrial fatty acid oxidation and the electron transport chain comprise a multifunctional mitochondrial protein complex. *J. Biol. Chem.* **294**, 12380–12391
361. Henriques, B. J., Katrine Jentoft Olsen, R., Gomes, C. M., and Bross, P. (2021) Electron transfer flavoprotein and its role in mitochondrial energy metabolism in health and disease. *Gene* **776**, 145407
362. Toogood, H. S., van Thiel, A., Basran, J., Sutcliffe, M. J., Scrutton, N. S., and Leys, D. (2004) Extensive domain motion and electron transfer in the human electron transferring flavoprotein.medium chain Acyl-CoA dehydrogenase complex. *J. Biol. Chem.* **279**, 32904–32912
363. Watmough, N. J., and Frerman, F. E. (2010) The electron transfer flavoprotein: ubiquinone oxidoreductases. *Biochim. Biophys. Acta* **1797**, 1910–1916
364. Lemmi, C. A., Pelikan, P. C., Geesaman, B., Seamon, E., Koyle, M., and Rajfer, J. (1990) Kinetics of cyclosporine A-induced inhibition of succinate-coenzyme Q dehydrogenase in rat renal cortical mitochondria. *Biochem. Med. Metab. Biol.* **43**, 214–225
365. Blanco, A., and Blanco, G. (2017) Chapter 9 – biological oxidations: bioenergetics. In: Blanco, A., Blanco, G., eds. *Medical Biochemistry*, Academic Press, Cambridge, MA: 177–204
366. Covarrubias, A. J., Perrone, R., Grozio, A., and Verdin, E. (2021) NAD⁺ metabolism and its roles in cellular processes during ageing. *Nat. Rev. Mol. Cell Biol.* **22**, 119–141
367. Hashimoto, T., Hussien, R., and Brooks, G. A. (2006) Colocalization of MCT1, CD147, and LDH in mitochondrial inner membrane of L6 muscle cells: evidence of a mitochondrial lactate oxidation complex. *Am. J. Physiol. Endocrinol. Metab.* **290**, E1237–E1244

368. Lautrup, S., Sinclair, D. A., Mattson, M. P., and Fang, E. F. (2019) NAD⁺ in brain aging and neurodegenerative disorders. *Cell Metab.* **30**, 630–655
369. Willson, J. A., Arienti, S., Sadiku, P., Reyes, L., Coelho, P., Morrison, T., *et al.* (2022) Neutrophil HIF-1 α stabilization is augmented by mitochondrial ROS produced *via* the glycerol 3-phosphate shuttle. *Blood* **139**, 281–286
370. Xiao, W., Wang, R. S., Handy, D. E., and Loscalzo, J. (2018) NAD(H) and NADP(H) redox couples and cellular energy metabolism. *Antioxid. Redox Signal.* **28**, 251–272
371. Cronshaw, M., Parker, S., and Arany, P. (2019) Feeling the heat: evolutionary and microbial basis for the analgesic mechanisms of photobiomodulation therapy. *Photobiomodul. Photomed. Laser Surg.* **37**, 517–526
372. Dumollard, R., Ward, Z., Carroll, J., and Duchen, M. R. (2007) Regulation of redox metabolism in the mouse oocyte and embryo. *Development* **134**, 455–465
373. Jian, C., Fu, J., Cheng, X., Shen, L. J., Ji, Y. X., Wang, X., *et al.* (2020) Low-dose sorafenib acts as a mitochondrial uncoupler and ameliorates nonalcoholic steatohepatitis. *Cell Metab.* **31**, 892–908
374. Gnaiger, E. (2021) Beyond counting papers – a mission and vision for scientific publication. *Bioenerg. Commun.* **2021**, 5. <https://doi.org/10.26124/bec:2021-0005>
375. Gall, T., Ioannidis, J. P. A., and Maniatis, Z. (2017) The credibility crisis in research: can economics tools help? *PLoS Biol.* **15**, e2001846
376. Brown, S. (2000) Does succinate oxidation yield FADH₂ or ubiquinol? *Biochem. Educ.* **28**, 52–54
377. Azzi, A. (2022) Oxidative stress: what is it? Can it be measured? Where is it located? Can it be good or bad? Can it be prevented? Can it be cured? *Antioxidants (Basel)* **11**, 1431
378. Gnaiger, E., Méndez, G., and Hand, S. C. (2000) High phosphorylation efficiency and depression of uncoupled respiration in mitochondria under hypoxia. *Proc. Natl. Acad. Sci. U. S. A.* **97**, 11080–11085
379. Donnelly, C., Schmitt, S., Cecatto, C., Cardoso, L. H. D., Komlódi, T., Place, N., *et al.* (2022) The ABC of hypoxia – what is the norm. *Bioenerg. Commun.* **2022**. <https://doi.org/10.26124/bec:2022-0012.v2>
380. Van't Hoff, J. H. (1901) Osmotic pressure and chemical equilibrium. *Nobel Lecture* **1921**, 5–10
381. Einstein, A. (1905) Über die von der molekularkinetischen Theorie der Wärme geforderte Bewegung von in ruhenden Flüssigkeiten suspendierten Teilchen. *Ann. Physik* **4**, 549–560
382. Nernst, W. (1921) Studies in chemical thermodynamics. *Nobel Lecture*, 353–362
383. Prigogine, I. (1967) *Introduction to Thermodynamics of Irreversible Processes*, 3rd ed, Interscience, New York: 147
384. Mitchell, P. (2011) Chemiosmotic coupling in oxidative and photosynthetic phosphorylation. *Biochim. Biophys. Acta Bioenerg.* **1807**, 1507–1538
385. Burtis, C. A., and Geary, T. D. (1994) Glossary of bioanalytical nomenclature – Part 1: general terminology, body fluids, enzymology, immunology (IUPAC Recommendations 1994). *Pure Appl. Chem.* **66**, 2587–2604
386. Grandoch, M., Flögel, U., Virtue, S., Maier, J. K., Jelenik, T., Kohlmoorgen, C., *et al.* (2019) 4-Methylumbelliferone improves the thermogenic capacity of brown adipose tissue. *Nat. Metab.* **1**, 546–559